Fact-checked by Grok 2 weeks ago

Immune system

The immune system is a of cells, tissues, organs, and molecules that protects the body from harmful pathogens, such as , viruses, fungi, and parasites, as well as from abnormal or damaged cells, including cancer cells, by distinguishing between healthy self-cells and foreign or unhealthy entities. This defense mechanism operates through coordinated responses that prevent or limit infections, promote healing, and maintain overall , with all immune cells originating from precursor hematopoietic stem cells in the . The system is essential for survival, as its dysfunction can lead to infections, autoimmune diseases, allergies, or immunodeficiencies. The immune system comprises two main interconnected branches: the and the , which together provide layered protection against threats. The innate immune system serves as the first line of defense, offering rapid, non-specific responses to a broad range of pathogens within minutes to hours of exposure. It includes physical barriers like the skin and mucous membranes, chemical defenses such as antimicrobial proteins in saliva and tears, and cellular components that engulf or destroy invaders through processes like and . Key innate cells include neutrophils, macrophages, dendritic cells, and natural killer (NK) cells, which recognize general danger signals via pattern recognition receptors that detect pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). In contrast, the provides slower but highly specific and long-lasting protection, developing immunological memory to enable faster and stronger responses upon re-exposure to the same . It is mediated primarily by lymphocytes—B cells and T cells—which recognize unique antigens on pathogens through diverse receptors generated by . B cells produce antibodies that neutralize extracellular threats, while T cells include helper T cells that coordinate responses, cytotoxic T cells that kill infected or abnormal cells, and regulatory T cells that prevent overreactions. Adaptive immunity is triggered by signals from the innate system, such as cytokines released by innate cells, and can lead to lifelong immunity, as seen in . Central to the immune system's function are specialized organs and tissues that support cell development, maturation, and activation. Primary lymphoid organs include the , where most immune cells originate and B cells mature, and the , where T cells develop and learn to tolerate self-antigens. Secondary lymphoid organs, such as lymph nodes, the , and mucosal-associated lymphoid tissues () like Peyer's patches in the gut, serve as sites where immune cells encounter antigens drained from tissues via lymphatic vessels or , initiating targeted responses. Lymphocytes constantly recirculate through and to patrol the body, ensuring vigilant surveillance.

Fundamentals

Definition and components

The immune system is a complex network of cells, tissues, and organs that collectively defends the body against invading pathogens such as , viruses, and parasites while distinguishing between and non-self components to prevent . This defense mechanism is essential for maintaining and survival in multicellular organisms. The primary lymphoid organs, where immune cells originate and mature, include the and the . Bone marrow, located in the cavities of bones, serves as the site of hematopoiesis for all blood cells, including immune cells. The , situated in the upper chest, is crucial for the maturation of certain immune cells during early development. Secondary lymphoid organs, which facilitate immune responses by concentrating antigens and immune cells, encompass lymph nodes, the , and (MALT). Lymph nodes are distributed throughout the body along lymphatic vessels, the filters blood in the , and MALT lines mucosal surfaces such as those in the gut and . Key cellular components of the immune system are leukocytes, or , which circulate in the and . Leukocytes are broadly categorized into families: granulocytes, including neutrophils, , and , which contain cytoplasmic granules; and agranulocytes, comprising lymphocytes (such as T cells and B cells) and monocytes. These cell types, numbering approximately 4.5 to 11.0 × 10⁹ per liter in human , form the mobile workforce of the immune system. The immune system, particularly its adaptive branch, represents an evolutionary hallmark of jawed vertebrates, emerging over 500 million years ago to provide specific and memory-based against diverse threats.

Layered defense strategy

The immune system's layered functions as a hierarchical, multi-tiered designed to detect, neutralize, and eliminate with increasing specificity and efficiency. This approach consists of three primary lines of : the first line comprising physical and chemical barriers that prevent pathogen entry; the second line involving the innate , which provides rapid, nonspecific ; and the third line encompassing the adaptive , which offers targeted, memory-based immunity. This progression ensures that most threats are halted early, while those that penetrate deeper encounter escalating countermeasures, minimizing the risk of infection establishment. Redundancy is a core feature of this strategy, with overlapping mechanisms across layers to compensate for potential failures in any single component, thereby enhancing overall resilience. For instance, if the first-line barriers are compromised, such as through a , this immediately activates the second-line innate response, recruiting phagocytic cells and initiating to contain the breach. Cooperation between layers further amplifies effectiveness; the innate system not only bridges the gap between barriers and adaptive responses but also primes the latter by presenting antigens to T and B cells, fostering a coordinated escalation. The serves as the rapid, nonspecific second layer, responding within minutes to hours to conserved features via receptors. This biological efficiency mirrors historical military analogies, such as defenses where outer walls deter invaders before inner fortifications engage, but prioritizes adaptive redundancy over static fortification to handle diverse microbial threats dynamically.

Barriers and Initial Defenses

Physical barriers

The acts as the body's primary physical barrier against entry, comprising the , a multilayered structure that prevents microbial penetration. The outermost layer, the , consists of dead filled with , a tough protein that provides mechanical strength and impermeability to water and microbes. Beneath this, viable epidermal layers feature tight junctions between , which seal intercellular spaces and restrict the passage of and toxins into deeper tissues. Mucous membranes line the respiratory, gastrointestinal, and urogenital tracts, forming additional physical barriers by trapping and expelling potential invaders. In the , ciliated epithelial cells propel mucus upward via coordinated beating of cilia, carrying trapped particles and microbes away from the lungs toward the for expulsion. Similarly, in the , peristaltic movements propel contents along the intestines, mechanically flushing pathogens while the mucosal sheds cells to remove adherent microbes. The urogenital tract employs urine flow during to mechanically wash out from the urethra and , reducing risk. Other specialized barriers include the , which covers the eye's surface and uses a thin epithelial layer with goblet cells to secrete protective , preventing microbial adhesion. The blood-brain barrier, formed by tight junctions between endothelial cells in cerebral capillaries, selectively restricts entry into the , maintaining a sterile environment for neural tissues. These physical structures collectively provide the first line of defense, often complemented by chemical mechanisms for enhanced protection.

Chemical and antimicrobial barriers

The immune system's chemical and antimicrobial barriers consist of soluble molecules and environmental factors secreted at epithelial surfaces that inhibit or eliminate pathogens before they can invade deeper tissues. These defenses complement physical barriers such as and mucosa by providing biochemical deterrence directly at sites of potential microbial entry. , an enzyme abundant in , , and , serves as a key agent by hydrolyzing the β-1,4 glycosidic bonds in bacterial , leading to degradation and osmotic primarily of . This mechanism disrupts bacterial integrity at mucosal surfaces, preventing colonization in the eyes, , and . Antimicrobial peptides, including defensins and cathelicidins, form another critical layer of defense through direct pathogen disruption. Defensins, such as α-defensins produced by neutrophils and β-defensins by epithelial cells, are cationic peptides that insert into microbial membranes, forming pores via barrel-stave, carpet, or toroidal models, which compromise membrane integrity and cause leakage of cellular contents. Similarly, cathelicidins like the human LL-37 peptide, expressed in epithelial cells and neutrophils, adopt an amphipathic α-helical structure to permeabilize bacterial, fungal, and viral envelopes, enhancing barrier protection at skin and mucosal interfaces. Acidic environments provide a non-proteinaceous chemical barrier that denatures microbial proteins and enzymes. In the , hydrochloric acid maintains a of 1-3, which effectively kills ingested pathogens by disrupting their structural components and metabolic processes. The vaginal mucosa similarly sustains an acidic around 3.5-4.5 through produced by resident lactobacilli, inhibiting the growth of harmful and yeasts while supporting beneficial . The normal , consisting of commensal microorganisms residing on , in the gut, and at other mucosal sites, acts as a biological barrier by outcompeting pathogens for nutrients and attachment sites, producing metabolites such as and , and stimulating host immune maturation to prevent colonization by harmful invaders. Additional factors like and pulmonary contribute targeted effects. , an iron-binding present in , , nasal secretions, and , sequesters free iron essential for bacterial proliferation, thereby starving pathogens and limiting infections at mucosal sites. In the lungs, pulmonary —lipoprotein complexes lining the alveoli—include collectins such as surfactant proteins A and D, which bind motifs on microbial surfaces, aggregate pathogens, and facilitate their clearance while also modulating local immune responses.

Innate Immune System

Pathogen recognition

The initiates detection through pattern receptors (PRRs), a class of germline-encoded proteins that identify conserved molecular signatures absent in healthy cells. These receptors enable rapid, non-specific of invading microbes and cellular damage, distinguishing from non-self without prior exposure. PRRs are expressed on immune and non-immune cells, including epithelial barriers and cells, and their triggers downstream inflammatory responses essential for defense. Key families of PRRs include Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs). Humans possess 10 functional TLRs (TLR1–TLR10), which are transmembrane proteins that detect extracellular and endosomal ligands; for instance, the discovery of TLRs as mammalian counterparts to the protein highlighted their role in signaling adaptive immunity activation. NLRs, numbering 22 in humans, are cytoplasmic sensors that recognize intracellular threats and include subfamilies like NOD1, , and , which form upon activation. RLRs, comprising RIG-I, , and the regulatory LGP2, are RNA helicases specialized in detecting cytosolic viral nucleic acids. PRRs primarily target pathogen-associated molecular patterns (PAMPs), microbial structures essential for pathogen survival but absent in vertebrates. Examples include lipopolysaccharide (LPS), a component of Gram-negative bacterial outer membranes recognized by TLR4; , the structural protein of bacterial flagella detected by TLR5; and double-stranded RNA (dsRNA), a replication intermediate of many viruses sensed by TLR3 and RLRs. These interactions initiate tailored responses, such as NF-κB-mediated for bacterial PAMPs or type I production for viral ones. Beyond PAMPs, PRRs also detect damage-associated molecular patterns (DAMPs), endogenous molecules released during host cell injury, , or stress, which amplify immune alerts to sterile . Common DAMPs include high-mobility group box 1 () protein, extracellular ATP, and crystals, which bind receptors like TLR4, , and RIG-I to mimic infection signals. This dual recognition ensures responses to both infectious and non-infectious threats. Ligand engagement by PRRs activates intracellular signaling pathways, often converging on the transcription factor. For TLRs, this involves adaptor proteins like MyD88 or TRIF, leading to IκB kinase phosphorylation, NF-κB nuclear translocation, and transcription of proinflammatory cytokines such as TNF-α, IL-1β, and IL-6. NLRs and RLRs similarly promote NF-κB activation via RIPK2 or MAVS adaptors, respectively, resulting in cytokine release that recruits and activates innate immune cells for pathogen clearance.

Innate immune cells

The innate immune system relies on a diverse array of specialized cells that provide rapid, non-specific defense against pathogens through mechanisms such as , , and . These cells originate primarily from hematopoietic stem cells in the and are mobilized to sites of via , which guide their migration along concentration gradients to orchestrate early inflammatory responses. Phagocytes form the cornerstone of innate cellular immunity, engulfing and destroying through followed by lysosomal degradation. Neutrophils, the most abundant granulocytes, are short-lived cells with a lifespan of hours to days in circulation; they are rapidly produced in the during infection and recruited to , where they contribute to formation by releasing antimicrobial contents after . Macrophages, derived from circulating monocytes that differentiate in , serve as long-lived, resident capable of sustained pathogen clearance and initial to bridge innate and adaptive responses; their lifespan can extend from weeks to months depending on and state. Dendritic cells, also monocyte-derived, excel in of pathogens and debris while migrating to lymph nodes to present antigens, thereby linking innate detection to adaptive . Natural killer (NK) cells provide cytotoxic defense against virus-infected and tumor cells without prior sensitization, comprising about 5-15% of circulating lymphocytes and produced in the with a lifespan of days to weeks. They induce target cell primarily through the release of perforin, which forms pores in the plasma membrane, and granzymes, serine proteases that enter cells to trigger caspase activation and programmed death. cells also mediate (ADCC) by recognizing antibody-coated targets via (FcγRIII) receptors, enhancing their perforin/granzyme-mediated killing. Other innate cells include , , and mast cells, which target larger parasites and modulate through granule release. , bone marrow-derived granulocytes with a lifespan of 8-12 days, specialize in combating helminth infections via and of cytotoxic granules containing major basic protein and peroxidase, which damage parasite membranes. and mast cells, both rich in and heparin-containing granules, promote upon IgE cross-linking or signals, releasing mediators that enhance and recruit other immune cells during allergic or parasitic responses; circulate briefly (hours to days) while tissue-resident mast cells persist for months.

Inflammatory processes

Inflammation represents a fundamental innate to or , orchestrating a coordinated cascade to eliminate harmful agents and initiate repair. This process begins rapidly upon detection of damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) by resident immune cells, such as macrophages and mast cells. The acute phase of inflammation unfolds in distinct stages, starting with vascular changes that facilitate immune cell access to the affected site. , primarily mediated by release from mast cells, increases blood flow, while elevated allows plasma proteins and fluid to extravasate, forming . These alterations, occurring within minutes, set the stage for cellular recruitment, where neutrophils marginate along vessel walls, adhere via selectins and , and migrate through the guided by chemotactic gradients. Key mediators drive these events, including cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), which amplify endothelial activation and leukocyte adhesion; that direct cell trafficking; and prostaglandins derived from metabolism, which sustain and pain sensitization. Complement activation further amplifies inflammation through its classic pathway, triggered by antibody-bound complexes, and alternative pathway, initiated by spontaneous or microbial surfaces, both converging to generate anaphylatoxins like C3a and C5a that promote permeability and . The hallmark clinical manifestations of acute inflammation, known as the cardinal signs, include redness (rubor) from hyperemia, heat (calor) due to increased blood flow, swelling (tumor) from , pain (dolor) induced by mediators like and prostaglandins, and loss of function () resulting from tissue disruption. Resolution of acute inflammation is an active process regulated by anti-inflammatory signals, such as IL-10 produced by macrophages and regulatory T cells, which suppresses pro-inflammatory production and promotes tissue repair. Concurrently, neutrophils undergo , a that limits further tissue damage by containing cytotoxic contents, with apoptotic cells subsequently phagocytosed by macrophages in a non-phlogistic manner that reinforces IL-10 release and dampens the response.

Complement and humoral innate responses

The constitutes a critical component of humoral innate immunity, comprising a of over 30 and membrane-bound proteins that provide rapid, nonspecific defense against . Activated through three distinct pathways, it enhances , promotes , and directly lyses target cells, all while being tightly regulated to avoid host tissue damage. The classical pathway initiates when C1q binds to antibody-pathogen complexes or certain acute-phase proteins, activating the serine proteases C1r and C1s, which cleave and to form the C4b2a. The alternative pathway begins spontaneously through of to C3(H2O), which binds factor B; factor D then cleaves factor B to generate the C3bBb, stabilized by on surfaces for amplification. The lectin pathway is triggered by mannose-binding lectin (MBL) or ficolins recognizing microbial carbohydrates, leading to activation of MASP-2, which cleaves and to produce the same C4b2a as in the classical pathway. All three pathways converge at cleavage by their respective convertases, generating C3a (an anaphylatoxin) and C3b, which deposits on pathogens and forms the (C4b2a3b or C3bBb3b) to propagate downstream effects. Central functions of the complement system include opsonization, where C3b coats microbes to facilitate recognition and uptake by via complement receptors. is mediated by C5a, a cleavage product of that attracts neutrophils and monocytes to infection sites, amplifying the inflammatory response initiated by earlier innate processes. occurs via the terminal pathway, in which C5b sequentially recruits , C7, C8, and multiple C9 molecules to assemble the membrane attack complex (C5b-9), forming transmembrane pores that disrupt pathogen membranes. Beyond complement proteins, other soluble humoral factors such as collectins and pentraxins contribute to innate defense. Collectins, including MBL, bind pathogen-associated molecular patterns to initiate the and promote opsonization. Pentraxins, a family of multimeric pattern recognition molecules, encompass short pentraxins like (CRP), which binds on damaged cells or microbes to activate the classical pathway via C1q, and the long pentraxin PTX3, produced at infection sites to opsonize fungi and regulate inflammation. To prevent autologous damage, the is regulated by soluble and membrane-bound inhibitors; notably, C1 esterase inhibitor (C1-INH) irreversibly binds and inactivates C1r, C1s, and MASP-2, thereby controlling classical and initiation while also modulating pathway activity through interactions with C3b. Additional regulators like and C4b-binding protein further decay convertases and limit amplification on host cells.

Adaptive Immune System

Antigen recognition and specificity

The adaptive immune system achieves precise antigen recognition through specialized receptors expressed on lymphocytes, enabling specific identification of pathogens and foreign molecules. B cells express B cell receptors (BCRs), which are membrane-bound forms of immunoglobulins consisting of two heavy and two light chains that form an -binding site. T cells, in contrast, express T cell receptors (TCRs), which are heterodimeric proteins predominantly composed of α and β chains (αβ TCRs) in most T cells, or γ and δ chains (γδ TCRs) in a smaller subset. These receptors are non-covalently associated with invariant signaling molecules, such as /CD79b for BCRs and CD3 for TCRs, which facilitate intracellular upon antigen binding. The specificity of these receptors arises from the clonal selection theory, which posits that each lymphocyte clone expresses a unique receptor generated during development, and only those clones binding antigen undergo proliferation and differentiation. This theory, formulated by Frank Macfarlane Burnet, explains how the immune system selects and expands rare antigen-specific cells from a diverse pool without prior exposure to the antigen. Receptor diversity is primarily generated through V(D)J recombination, a somatic process in developing lymphocytes where variable (V), diversity (D, for some chains), and joining (J) gene segments are randomly rearranged to form the variable region of the receptor. Discovered by Susumu Tonegawa, this mechanism allows for the combinatorial assembly of gene segments, junctional flexibility during recombination, and additional processes like P-nucleotides and N-nucleotides to create immense variability. In humans, V(D)J recombination, combined with heavy-light chain pairing for BCRs and α-β chain pairing for TCRs, theoretically generates over 10^11 distinct receptor specificities, far exceeding the number of lymphocytes in the body and providing broad coverage against potential antigens. This diversity ensures that virtually any foreign epitope can be recognized, while the finite number of cells expresses a subset of these possibilities. Antigen engagement by these receptors typically requires presentation in the context of major histocompatibility complex (MHC) molecules for TCRs, linking recognition to the subsequent processing and display of antigens. To prevent autoimmunity, central tolerance mechanisms eliminate or inactivate self-reactive lymphocytes during development. In the thymus, developing T cells undergo negative selection, where those with high-affinity TCRs for self-peptides presented by MHC on thymic epithelial or dendritic cells are induced to undergo apoptosis, thus depleting potentially autoreactive clones. Similarly, in the bone marrow, immature B cells expressing BCRs that strongly bind self-antigens encounter negative selection through clonal deletion, receptor editing (secondary V(D)J recombination to alter specificity), or anergy, ensuring that mature B cells exiting the marrow are largely tolerant to self. These processes collectively shape the repertoire to favor foreign antigen recognition while minimizing self-reactivity.

Antigen presentation

Antigen presentation is the process by which cells display fragments of antigens on their surface using (MHC) molecules to alert T cells of the . This mechanism allows the adaptive to recognize and respond to intracellular pathogens, extracellular threats, and abnormal cells. MHC molecules bind processed peptides in specific intracellular compartments and transport them to the cell surface, where they are surveyed by T cell receptors. MHC class I molecules are expressed on nearly all nucleated cells and present endogenous antigens, such as those derived from cytosolic proteins including viral or tumor-associated peptides, to CD8+ T cells. In the classical cytosolic pathway, proteins in the cytoplasm are ubiquitinated and degraded by the proteasome into short peptides (typically 8–10 amino acids), which are then transported into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP). Within the ER, peptides are loaded onto nascent MHC class I molecules in the peptide-loading complex, involving chaperones like tapasin, calreticulin, and ERp57, before the complex traffics to the cell surface. MHC class II molecules are primarily expressed on professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells, and they present exogenous antigens, like those from or engulfed by , to + T cells. In the endosomal pathway, internalized antigens are degraded in acidic endosomal/lysosomal compartments by proteases such as cathepsins, while αβ dimers associate with the invariant (Ii) in the to prevent premature peptide binding and direct the complex to MHC class II compartments (MIICs). The invariant is proteolytically cleaved, leaving the class II-associated invariant peptide (CLIP) in the peptide-binding groove; HLA-DM then facilitates CLIP removal and exchange for antigenic peptides (typically 13–25 ), enabling stable -peptide complexes to reach the plasma membrane. A specialized process called allows dendritic cells to present exogenous antigens on molecules, bridging innate and adaptive immunity by activating + T cells against extracellular pathogens or tumors without direct of the presenting cell. This occurs via two main pathways: the phagosome-to- route, where antigens escape endosomes to the cytosol for proteasomal and TAP-dependent loading, and the vacuolar route, involving intra-phagosomal and TAP-independent peptide loading onto recycled . Dendritic cells are uniquely efficient at cross-presentation due to factors like Sec22b-mediated ER-phagosome fusion and low lysosomal . Non-classical MHC class I molecules, such as and , present a restricted set of peptides and primarily regulate natural killer () cell activity rather than conventional T cell responses. binds leader peptides from other HLA class I molecules and inhibits cells through interaction with CD94/NKG2A receptors, promoting in contexts like and transplantation. Similarly, presents diverse peptides and delivers inhibitory signals to cells via receptors like ILT2 and KIR2DL4, contributing to immune evasion in tumors and viral infections. These molecules are expressed on subsets of APCs and stressed cells, fine-tuning innate immunity alongside classical presentation pathways. The antigens presented via MHC molecules ultimately trigger cell-mediated immune responses by activating cytotoxic and helper T cells.

Cell-mediated immunity

Cell-mediated immunity refers to the adaptive immune response orchestrated primarily by T lymphocytes, which directly eliminate infected or abnormal cells and coordinate other immune functions without relying on antibodies. Unlike , this arm targets intracellular pathogens such as viruses and intracellular bacteria, as well as transformed cells like tumors, through cell-to-cell contact and signaling. T cells recognize antigens presented on (MHC) molecules by antigen-presenting cells, leading to their activation and differentiation into effector subsets. T cell activation follows a two-signal model, where the first signal is provided by the (TCR) binding to peptide-MHC complexes, and the second costimulatory signal is delivered via on T cells interacting with B7-1 () or B7-2 () on antigen-presenting cells. This prevents anergy and promotes , production, and ; without it, T cells may become unresponsive or undergo . Cytotoxic CD8+ T cells, also known as killer T cells, directly lyse target cells through two main mechanisms: granule and death receptor signaling. In the granule pathway, they release perforin, which polymerizes to form pores in the target , allowing granzymes to enter and activate , leading to . Alternatively, CD8+ T cells induce via Fas ligand (FasL) binding to receptors on targets, triggering the extrinsic death pathway through activation. These cells primarily target virally infected cells and tumor cells expressing altered antigens. Helper + T cells amplify and direct immune responses by secreting cytokines that modulate other cells. Th1 subsets produce interferon-gamma (IFN-γ), which activates macrophages to enhance and intracellular killing of pathogens. Th2 cells secrete interleukin-4 (IL-4), promoting differentiation and production in humoral responses. Th17 cells release IL-17, recruiting and activating neutrophils to combat extracellular bacteria and fungi at mucosal sites. Regulatory T cells (Tregs), a subset of + T cells expressing , maintain by suppressing excessive responses through secretion and cell contact. They produce IL-10 and transforming growth factor-beta (TGF-β), which inhibit proinflammatory production by effector T cells and antigen-presenting cells. This suppression prevents and dampens after clearance. Gamma delta (γδ) T cells represent a distinct lineage that provides rapid, innate-like responses at epithelial and mucosal barriers, independent of MHC restriction. They surveil for stress signals, such as phosphoantigens from infected or transformed cells, and respond quickly by producing cytokines like IFN-γ or directly lysing targets. In mucosal tissues, γδ T cells contribute to tissue homeostasis and early defense against pathogens before αβ T cell involvement. Helper CD4+ T cells also support antibody-mediated immunity by providing cytokines that enhance responses.

Antibody-mediated immunity

Antibody-mediated immunity, a key component of the adaptive , relies on B lymphocytes () to produce soluble antibodies that target and neutralize extracellular pathogens such as and viruses. Upon encountering an , naive B cells become activated and differentiate into antibody-secreting plasma cells, generating a humoral response that provides rapid and specific defense against infections. This process contrasts with by focusing on soluble effectors rather than direct cellular , enabling antibodies to circulate systemically and access diverse tissues. B cell activation occurs through two primary pathways: T cell-dependent (TD) and T cell-independent (). In the TD pathway, which predominates for protein antigens, internalize and present fragments to CD4+ T helper cells in secondary lymphoid organs, leading to cognate interactions that drive B cell proliferation and differentiation within germinal centers. These germinal centers facilitate class-switch recombination, transitioning antibody production from the initial IgM isotype to more specialized forms like IgG, IgA, or IgE, which confer enhanced effector functions tailored to the infection site. In contrast, the TI pathway activates directly via multivalent antigens, such as bacterial with repeating epitopes, bypassing T cell involvement and typically yielding short-lived IgM responses without class switching or extensive maturation. Antibodies, or immunoglobulins, exhibit a conserved Y-shaped structure composed of two identical heavy chains and two identical light chains, linked by bonds and non-covalent interactions, with a total molecular weight of approximately 150 kDa for the monomeric form. The antigen-binding fragment () regions, located at the tips of the Y arms, contain variable domains that confer specificity to the , while the crystallizable fragment () region at the base mediates interactions with immune cells and complement proteins. Antibodies exist in five main isotypes—IgA, IgD, IgE, IgG, and IgM—distinguished by their heavy chain constant regions, which determine their distribution and functions; for instance, IgM forms a pentameric structure for high-avidity early responses, whereas monomeric IgG predominates in and can cross the to provide neonatal immunity. The effector functions of antibodies enable multifaceted pathogen clearance. Neutralization occurs when antibodies bind to viral or toxin epitopes, sterically hindering attachment to host cells and preventing . Opsonization enhances by coating pathogens with antibodies, allowing Fc receptors on macrophages and neutrophils to recognize and engulf the targets efficiently. Complement activation is initiated via the classical pathway when the C1q component binds to the Fc region of IgM or IgG, triggering a that forms membrane attack complexes to lyse or further opsonizes them with C3b. Additionally, (ADCC) recruits natural killer cells, which bind antibody-coated cells via Fcγ receptors and release perforin and granzymes to induce target . Following activation, B cells differentiate into plasma cells, long-lived effector cells residing primarily in the that secrete thousands of antibodies per second to sustain . During the TD response in germinal centers, affinity maturation refines antibody quality through , a process where activation-induced cytidine deaminase introduces point into the variable regions of immunoglobulin genes at rates up to 10^6 times higher than baseline. Subsequent selection favors B cells with mutations enhancing affinity, leading to progressively higher-avidity antibodies over iterative cycles of mutation and competition for and survival signals. This maturation not only amplifies protective efficacy but also generates memory B cells derived from activated B cells, enabling faster and stronger responses upon re-exposure.

Immunological memory

Immunological memory refers to the adaptive immune system's ability to retain information about previously encountered pathogens, allowing for accelerated and amplified responses during subsequent exposures. This phenomenon is orchestrated by long-lived memory B cells and memory T cells, which arise from the primary and persist in lymphoid and non-lymphoid tissues for years or even lifetimes. Unlike the , which lacks memory, these adaptive memory cells enable protection against reinfection, forming the basis for immunological . Memory B cells, often marked by CD27 expression, differentiate through germinal center reactions involving and affinity maturation, leading to high-affinity production upon reactivation. They include subsets analogous to T cell memory, with some recirculating through lymphoid organs and others residing in tissues for localized responses. Memory T cells, conversely, are heterogeneous and classified into central memory T cells (T_CM), which home to lymph nodes via CCR7 and CD62L expression for sustained proliferation potential, and effector memory T cells (T_EM), which patrol peripheral tissues lacking these homing receptors to provide immediate effector functions like release. Both subsets are maintained by s such as IL-7 and IL-15, ensuring longevity without ongoing stimulation. The primary immune response exhibits a lag phase of approximately 4-7 days before detectable production, dominated by IgM with lower affinity and magnitude, peaking around 7-10 days post-exposure. In contrast, secondary responses triggered by memory cells show a markedly reduced of 1-3 days, transitioning rapidly to high-affinity IgG production with titers 100- to 1,000-fold higher and more sustained. This enhanced kinetics and scale stem from the pre-existing clonal expansion of memory cells, minimizing the need for activation. Epigenetic modifications, including , histone acetylation, and , underpin memory cell maintenance by locking in stable profiles that facilitate swift reactivation. For instance, in memory T cells, these changes poise loci for rapid transcription of effector genes like those encoding cytokines, independent of . Similar epigenetic programming in memory B cells supports their quiescent state while priming for into cells. Immunological memory is not indefinite; waning over time, particularly in antibody levels, can reduce protection, as observed in vaccines where humoral responses decline months post-immunization. Booster vaccinations counteract this by reinvigorating cells, eliciting responses comparable to or exceeding secondary exposures and enhancing long-term against evolving pathogens. In immunodeficiencies, impaired memory formation leads to diminished secondary responses and increased susceptibility to recurrent infections.

Regulation and Homeostasis

Hormonal influences

The endocrine system exerts profound bidirectional influences on the immune system, with hormones modulating immune cell function, production, and inflammatory responses, while immune signals in turn regulate secretion. This interplay ensures but can also contribute to immune dysregulation under or hormonal imbalance. Key hormones from the hypothalamic-pituitary-adrenal () axis, gonads, and gland play central roles in this regulation. Stress hormones, particularly like , suppress by inhibiting the NF-κB, which reduces the expression of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α. This anti-inflammatory action occurs through glucocorticoid receptor-mediated repression of activity in immune cells like macrophages and T lymphocytes, thereby limiting excessive immune responses during stress. Catecholamines, including epinephrine and norepinephrine released during acute stress, enhance natural killer (NK) cell activity by promoting their redistribution from marginal to circulating pools, increasing NK cell numbers and against virally infected or tumor cells via β-adrenergic receptor signaling. Sex hormones exhibit sexually dimorphic effects on immunity, with generally enhancing by promoting differentiation, production, and Th2 responses, while testosterone favors by supporting Th1 responses and suppressing excessive inflammation. These effects contribute to observed sex differences in prevalence, where females show stronger antibody-mediated responses. Fluctuations during the further modulate immunity, with higher levels in the boosting titers and NK cell activity, whereas progesterone dominance in the dampens pro-inflammatory responses to maintain tolerance. Thyroid hormones, (T3) and thyroxine (T4), regulate proliferation and differentiation by binding to thyroid hormone receptors on T and B cells, enhancing mitogen-induced proliferation and secretion in euthyroid states. amplifies T and B cell responses, increasing IgG production and T cell activation, while impairs these processes, leading to reduced immune competence. This modulation occurs via genomic effects on and non-genomic pathways influencing . The immune-endocrine axis is bidirectional, with pro-inflammatory cytokines like IL-1, IL-6, and TNF-α stimulating the HPA axis to increase release, thereby providing to resolve . This cytokine-driven activation of (CRH) and (ACTH) secretion helps coordinate systemic responses to or . Nutritional factors, such as adequate intake of precursors for synthesis, can interact with this axis to support balanced immune regulation.

Nutritional and environmental factors

Nutritional and environmental factors play a critical role in maintaining immune by modulating innate and adaptive responses, influencing production, and supporting microbial balance in the host. Deficiencies or excesses in these factors can disrupt immune regulation, leading to heightened or impaired defenses against pathogens. Key elements include vitamins derived from and , sleep patterns, physical activity levels, and the gut , each interacting with immune cells to promote resilience or vulnerability. Vitamin D, primarily synthesized in upon exposure to ultraviolet B from , acts as a key regulator of immune function through its active form, 1,25-dihydroxyvitamin D3, which binds to the (VDR) expressed on various immune cells such as macrophages, dendritic cells, and T lymphocytes. This binding enhances the expression of , notably cathelicidin (LL-37), which exhibits broad-spectrum activity against , viruses, and fungi by disrupting microbial membranes and promoting in infected cells. VDR signaling also modulates T-cell , favoring regulatory T cells to dampen excessive while bolstering innate defenses. Insufficient levels, common in populations with limited sun exposure, correlate with reduced cathelicidin production and increased susceptibility to respiratory infections. Adequate , typically 7-9 hours per night for adults, is essential for balancing pro- and cytokines, supporting T-cell , and maintaining natural killer (NK) cell activity. During , the immune system undergoes restorative processes, including the release of and , which enhance production and phagocytic function. Chronic disrupts this balance by elevating proinflammatory cytokines like IL-6 and TNF-α, while suppressing IL-10, thereby increasing susceptibility to infections and exacerbating inflammatory conditions. Experimental studies show that even partial sleep restriction over several nights impairs leukocyte function and heightens vulnerability to viral pathogens. Moderate exercise, such as 30-60 minutes of aerobic activity most days, enhances immune surveillance by increasing circulating cells and promoting IL-6 release from contracting muscles, which acts as a to coordinate responses and improve metabolic health. This activity facilitates leukocyte trafficking, with enhanced migration of immune cells to tissues via upregulated chemokine receptors like on CD8+ T and cells. In contrast, excessive or prolonged intense exercise can suppress immune function temporarily, reducing NK cell cytotoxicity and increasing , which may elevate risk in athletes. Regular moderate regimens, however, cumulatively strengthen adaptive immunity through improved lymph flow and reduced chronic inflammation. The gut microbiome, comprising trillions of commensal bacteria, trains the immune system by producing (SCFAs) such as butyrate, propionate, and from , which signal through G-protein-coupled receptors on immune cells to promote regulatory T-cell and IgA by cells in the gut mucosa. These SCFAs enhance epithelial barrier integrity and modulate function, fostering tolerance to harmless antigens while priming defenses against pathogens. , characterized by reduced microbial diversity often linked to poor or antibiotics, diminishes SCFA levels and is associated with heightened via increased Th17 cell activity and leaky gut permeability, as evidenced in post-2020 studies on and metabolic disorders. Restoring microbiome balance through fiber-rich s supports immune across distant sites like the lungs and skin.

Tissue repair mechanisms

Tissue repair mechanisms in the immune system are integral to , transitioning from the to orchestrated processes that restore integrity and function. Following initial , where immune cells clear debris and pathogens, repair begins with , involving platelet aggregation to form a clot that stabilizes the and provides a scaffold for cellular infiltration. Platelets release growth factors such as (PDGF) and transforming growth factor-beta (TGF-β), which recruit fibroblasts and endothelial cells to initiate subsequent phases. The inflammatory phase overlaps with early repair, dominated by macrophages that shift from pro-inflammatory M1 to anti-inflammatory M2 phenotypes to promote resolution and tissue remodeling. M2 macrophages secrete anti-inflammatory cytokines like interleukin-10 (IL-10) and TGF-β, facilitating debris clearance while suppressing excessive inflammation to prevent chronic damage. Regulatory T cells (Tregs) further modulate this process by inhibiting fibrotic responses through IL-10 and TGF-β production, ensuring balanced repair without overproduction of extracellular matrix. In the proliferation phase, immune-derived signals drive activation and , with macrophages and T cells upregulating (VEGF) to stimulate endothelial cell and new vessel formation essential for nutrient delivery. , recruited by immune signals, deposit and other components to form , supported by mesenchymal stem cells (MSCs) from that differentiate into fibroblasts and secrete paracrine factors enhancing repair. MSCs interact with macrophages to polarize them toward states, amplifying and pro-regenerative effects. The remodeling phase involves matrix metalloproteinases (MMPs) from immune cells and fibroblasts to reorganize collagen, replacing type III with stronger for tensile strength, a process that can last months. Tregs limit excessive during this stage by suppressing differentiation. When repair mechanisms fail, mammalian tissues often result in scarring due to dysregulated immune responses, such as persistent activity leading to , whereas lower vertebrates like salamanders achieve scarless regeneration through rapid and Treg-mediated suppression of . This contrast highlights the immune system's pivotal role in determining regenerative outcomes.

Disorders of Immunity

Primary and secondary immunodeficiencies

Primary immunodeficiencies are a group of congenital disorders caused by genetic defects that impair the development or function of immune cells, leading to increased susceptibility to infections. These conditions arise from mutations in over 550 genes, with more than 555 distinct disorders identified as of 2024. The incidence of primary immunodeficiencies is estimated at approximately 1 in 1200 individuals as of 2025. Common examples include (SCID), often resulting from (ADA) deficiency, which disrupts development and function, and , caused by mutations in the gene that prevent B-cell maturation and antibody production. In contrast, secondary immunodeficiencies are acquired conditions that compromise immune function through external factors, rather than inherent genetic flaws. These include infection leading to acquired immunodeficiency syndrome (AIDS), which progressively depletes T cells and impairs overall immune surveillance; , which exacerbates immune impairment by limiting nutrient availability for immune cell production and function; and treatments such as , which suppress activity and reduce counts in patients with malignancies. Both primary and secondary immunodeficiencies manifest with recurrent, severe infections—such as , , and skin infections—as well as in affected children, characterized by poor weight gain and growth delays due to chronic illness and . Management of these disorders focuses on preventing infections and restoring immune competence, particularly for primary forms. Immunoglobulin replacement therapy provides exogenous antibodies to compensate for deficiencies in , while (HSCT) replaces defective immune cells with healthy donor cells. represents a targeted approach for specific primary immunodeficiencies, such as ADA-SCID; Strimvelis, an lentiviral vector-based therapy that corrects the ADA in autologous hematopoietic stem cells, was approved in 2016 and has shown sustained immune reconstitution in treated patients, with marketing authorization transferred to in 2024 to ensure continued availability. For secondary immunodeficiencies, treatment primarily addresses the underlying cause, such as antiretroviral therapy for or nutritional support for , alongside supportive measures like prophylactic antibiotics.

Autoimmune diseases

Autoimmune diseases arise when the immune system erroneously targets and damages the body's own tissues and cells, leading to chronic inflammation and organ dysfunction. These conditions affect approximately 5-10% of the global population, with estimates indicating a combined prevalence of around 10% in developed countries, though exact figures vary by region and diagnostic criteria. Notably, about 78% of individuals with autoimmune diseases are female, a disparity linked to hormonal influences such as , which modulates immune responses by promoting B-cell activation and production while enhancing T-cell differentiation toward pro-inflammatory phenotypes. This sex bias underscores the interplay between , hormones, and environmental triggers in disease susceptibility. The of autoimmune diseases fundamentally involves the breakdown of immune self-tolerance, the mechanisms that normally prevent immune responses against self-antigens. Central tolerance occurs in the and , where autoreactive T and B cells are deleted or rendered anergic during development; failures here, such as defective negative selection, allow self-reactive lymphocytes to enter circulation. mechanisms, including anergy (functional inactivation of autoreactive cells), deletion, and suppression by regulatory T cells (Tregs), further maintain in mature immune cells; defects in Treg function or number, often due to genetic mutations in or IL-2 signaling, impair this suppression and contribute to . Primary immunodeficiencies can exacerbate this risk by increasing susceptibility to infections, which may trigger or perpetuate autoimmune responses through chronic immune activation. Key mechanisms driving tolerance breakdown include molecular mimicry, where foreign antigens (e.g., from pathogens) share structural similarities with self-antigens, leading to cross-reactive immune attacks; this is implicated in initiating following infections. Epitope spreading occurs when initial immune responses to a self-antigen expand to unrelated s on the same or different autoantigens, amplifying tissue damage during chronic inflammation. Genetic factors also play a pivotal role, with (HLA) alleles conferring susceptibility; for instance, is strongly associated with (RA), increasing risk by facilitating presentation of arthritogenic peptides to autoreactive T cells and promoting production. Representative examples illustrate these processes. In type 1 diabetes, autoreactive T cells infiltrate pancreatic islets, leading to beta-cell destruction and insulin deficiency; molecular mimicry with viral proteins and epitope spreading to islet autoantigens like insulin and GAD65 drive the progressive loss of glucose homeostasis. Multiple sclerosis (MS) involves T-cell and B-cell mediated demyelination in the central nervous system, where breakdown of blood-brain barrier tolerance allows cross-reactive responses to myelin basic protein, resulting in axonal damage and neurological deficits. Systemic lupus erythematosus (SLE) features production of antinuclear antibodies (ANAs) that form immune complexes, causing widespread inflammation in skin, joints, and kidneys; central and peripheral tolerance failures enable hyperactive B cells to generate these autoantibodies against nuclear components like DNA and histones.

Allergic and hypersensitivity reactions

Allergic and hypersensitivity reactions represent exaggerated immune responses to otherwise harmless antigens, such as , proteins, or environmental allergens, leading to tissue damage and clinical symptoms. These reactions are primarily mediated by the and can range from mild discomfort to life-threatening conditions like . Unlike protective immunity, hypersensitivity arises when the immune system misinterprets benign substances as threats, often involving specific or T-cell mechanisms that amplify . The provides a foundational framework for understanding these reactions, categorizing them into four types based on the underlying immunological processes. Type I hypersensitivity, also known as immediate hypersensitivity, is IgE-mediated and occurs rapidly upon re-exposure to an . In this process, allergen-specific IgE antibodies bind to high-affinity receptors (FcεRI) on the surface of mast cells and ; subsequent allergen cross-linking triggers mast cell , releasing preformed mediators like , as well as newly synthesized leukotrienes and prostaglandins. induces , increased , smooth muscle contraction, and mucus secretion, resulting in symptoms such as urticaria, , or . A classic example is peanut-induced , where systemic can cause and airway obstruction within minutes. Type II hypersensitivity involves antibodies (typically IgG or IgM) directed against antigens on cell surfaces or components, leading to . The antibodies bind to target cells, activating complement or recruiting natural killer cells and macrophages via (ADCC), which results in cell or . This type is exemplified by , where antibodies target antigens, causing their destruction in the or via complement-mediated and subsequent . Another instance is transfusion reactions, where mismatched blood group antibodies attack donor erythrocytes. Type III hypersensitivity arises from the deposition of immune complexes—formed by soluble antigens and IgG or IgM antibodies—in tissues, particularly in vessel walls or synovial spaces. These complexes activate complement, attracting neutrophils that release lysosomal enzymes and , causing local and tissue injury. In systemic lupus erythematosus (SLE), immune complexes contribute to through deposition in synovium, leading to complement and . Serum sickness, often triggered by drugs like penicillin, similarly involves circulating complexes that deposit in kidneys and , producing fever, , and arthralgias. Type IV hypersensitivity, or delayed-type hypersensitivity, is mediated by T cells rather than antibodies and develops over 48–72 hours. Antigen-presenting cells process and present the to + T helper cells, which differentiate into effector subsets (e.g., Th1 or Th17) that release cytokines like IFN-γ and TNF-α, recruiting and activating macrophages. This leads to localized inflammation and tissue damage, as seen in from allergens like or , where sensitized T cells infiltrate the skin, causing eczematous lesions. Type IV reactions can overlap briefly with chronic inflammation in persistent exposures but remain distinct in their cell-mediated nature. Atopy refers to a genetic predisposition to develop IgE-mediated hypersensitivity reactions, characterized by an imbalance in immune responses favoring Th2 cells over Th1 or Th17 pathways. Individuals with atopy exhibit heightened production of Th2 cytokines such as IL-4, IL-5, and IL-13, which promote B-cell class switching to IgE and eosinophil recruitment, skewing the immune environment toward allergic inflammation. This predisposition is polygenic, with variants in genes like FLG (filaggrin) and IL4RA increasing susceptibility, often manifesting as the "atopic march" from eczema to allergic rhinitis and asthma. Environmental factors, including early-life exposures, interact with this genetic background to exacerbate Th2 skewing. Common manifestations of hypersensitivity include , driven by bronchial hyperreactivity where inhaled allergens provoke exaggerated airway contraction and hypersecretion via IgE-dependent activation. In , Th2-skewed responses lead to eosinophilic infiltration and chronic airway remodeling, with symptoms like wheezing and dyspnea triggered by or dust mites. Food allergies, predominantly Type I, affect approximately 5–8% of children and involve rapid IgE-mediated reactions to proteins in , , eggs, or , potentially causing oral itching, gastrointestinal distress, or . The global prevalence of allergic diseases has risen significantly, now impacting 10–30% of children in developed regions, attributed to factors like the and urbanization reducing microbial diversity.

Chronic inflammatory conditions

Chronic inflammatory conditions represent a state of prolonged, low-grade immune that persists beyond the resolution of an initial insult, leading to tissue damage and . Unlike acute , which is typically self-limiting and protective, chronic involves sustained recruitment of immune cells such as macrophages and lymphocytes, resulting in the release of pro-inflammatory mediators that perpetuate the response. This dysregulation can arise from unresolved acute , where failure to clear pathogens or debris leads to ongoing signaling through receptors. In , chronic drives the formation of arterial plaques through the accumulation of lipid-laden macrophages and foam cells in the vessel wall, promoting and plaque instability. (IBD), encompassing and , features persistent mucosal mediated by the , which activates caspase-1 to process pro-IL-1β and induce in epithelial cells, exacerbating barrier dysfunction. These conditions highlight how immune dysregulation can target specific tissues, with involving adaptive responses to oxidized and IBD linked to dysbiosis-induced innate signaling. Key mechanisms include cytokine storms characterized by elevated levels of interleukin-6 (IL-6) and tumor necrosis factor (TNF), which amplify immune cell recruitment and survival while suppressing pathways. activation plays a central role, as these cells respond to TNF and IL-6 by proliferating and depositing , contributing to in chronic settings. reactions may occasionally trigger such persistence, though chronic forms are distinguished by their indolent progression. Idiopathic chronic inflammatory conditions, where no specific trigger is identified, include , marked by non-caseating granulomas formed through T helper 1 cell-dominated responses involving IFN-γ production by alveolar macrophages. presents with systemic inflammation, high levels, and , driven by innate immune hyperactivity without evident . Metabolic links further underscore chronic inflammation's breadth, as obesity induces low-grade inflammation via adipokines like and , which promote infiltration into and systemic elevation. Post-2020 observations in reveal persistent , with elevated IL-6 and TNF correlating to and sequelae, potentially due to viral remnants sustaining .

Medical Applications

Immunosuppressive therapies

Immunosuppressive therapies encompass a range of pharmacological agents and interventions designed to modulate or suppress excessive immune responses, primarily to prevent organ transplant rejection or manage autoimmune diseases. These therapies target key components of the immune system, such as T-cell activation, production, and B-cell function, while balancing the risk of over-suppression that could lead to infections or malignancies. Calcineurin inhibitors, including cyclosporine and , form a of maintenance in solid . These agents bind to intracellular immunophilins— for cyclosporine and FK-binding protein for —forming complexes that inhibit the phosphatase activity of . This blockade prevents the dephosphorylation and nuclear translocation of nuclear factor of activated T cells (NFAT), thereby disrupting the transcription of interleukin-2 (IL-2) and other cytokines essential for T-cell and . In clinical practice, cyclosporine and significantly reduce acute rejection rates in , liver, and heart transplants, with often preferred due to its potency and lower incidence of cosmetic side effects like . Corticosteroids, such as prednisone, exert broad immunosuppressive effects by binding to glucocorticoid receptors, which translocate to the nucleus and interact with transcription factors like nuclear factor kappa B (NF-κB). This interaction, known as transrepression, inhibits NF-κB's ability to promote pro-inflammatory gene expression, including cytokines such as IL-1, IL-6, and TNF-α. Prednisone is commonly used in induction regimens for transplant recipients and as a first-line agent in autoimmune conditions like rheumatoid arthritis and systemic lupus erythematosus, often in combination with other immunosuppressants to minimize doses and side effects. Monoclonal antibodies provide targeted by depleting specific immune cell populations or neutralizing key cytokines. Rituximab, a chimeric anti-CD20 , induces B-cell depletion through mechanisms including (ADCC), (CDC), and direct of CD20-positive B cells, thereby reducing production that contributes to rejection or . It is employed off-label in transplant settings for antibody-mediated rejection and in autoimmune diseases such as . Infliximab, a chimeric anti-TNF-α , neutralizes soluble and membrane-bound TNF-α, preventing its binding to receptors and subsequent activation of inflammatory cascades; this is particularly effective in autoimmune disorders like and , though its use in transplantation is more limited to cases of refractory rejection. These therapies are primarily applied to prevent allograft rejection in , where regimens combining inhibitors, corticosteroids, and sometimes monoclonal antibodies achieve graft survival rates exceeding 90% at one year for transplants. In , they mitigate tissue damage from self-reactive immune responses, as seen with in . However, a major side effect across all classes is heightened susceptibility to infections due to impaired pathogen clearance; for instance, inhibitors and corticosteroids increase the risk of opportunistic infections like and pneumonia by 2- to 5-fold in transplant patients. Other complications include from inhibitors and metabolic disturbances from corticosteroids, necessitating vigilant monitoring and prophylactic antimicrobials.

Immunostimulatory approaches

Immunostimulatory approaches encompass therapeutic strategies designed to augment the immune system's capacity to recognize and combat pathogens or aberrant cells, often by directly activating innate and adaptive responses. These methods contrast with immunosuppressive therapies by promoting immune activation rather than inhibition, and they play a critical role in treating infections, enhancing efficacy, and supporting antitumor immunity. Key modalities include administration, use, modulation, and nutritional interventions that bolster overall immune competence. Cytokine therapy leverages the administration of naturally occurring signaling molecules to amplify immune effector functions. , for instance, exhibits both antiviral and immunomodulatory properties, making it a cornerstone treatment for . Pegylated IFN-α is used as an alternative therapy for in select patients, where it induces sustained viral suppression in a subset of patients by enhancing cytotoxic T-cell responses and inhibiting . Similarly, high-dose interleukin-2 (IL-2) has been approved for advanced , where it promotes the expansion and activation of cytotoxic T cells and natural killer cells, leading to durable complete or partial tumor regressions in approximately 5-10% of patients despite significant . These therapies highlight cytokines' potential to redirect immune , though their use is tempered by side effects such as flu-like symptoms for IFN-α and vascular leak syndrome for IL-2. Adjuvants are compounds incorporated into vaccines or immunotherapies to potentiate antigen-specific responses by stimulating innate immunity. Aluminum salts, such as , represent the most widely used adjuvants and primarily elicit a Th2-biased humoral response by recruiting neutrophils, , and dendritic cells to the injection site, thereby prolonging and enhancing production. In contrast, MF59, an oil-in-water of , more broadly activates innate signals by inducing the release of and cytokines like ATP, which recruit monocytes and promote a mixed Th1/Th2 response, resulting in superior cellular and compared to in certain vaccines. These mechanisms underscore adjuvants' role in bridging innate danger sensing to adaptive memory formation without directly targeting specific pathogens. Immune checkpoint inhibitors briefly exemplify targeted immunostimulation by relieving inhibitory signals on T cells. blockers, such as , bind to the programmed death-1 receptor on activated T cells, preventing its interaction with PD-L1 on tumor cells and thereby reinvigorating exhausted antitumor responses. Approved for multiple malignancies, has demonstrated objective response rates of 20-40% in PD-L1-positive advanced solid tumors, establishing it as a pivotal tool in . Probiotics and immunonutrition offer non-pharmacological avenues for general immune enhancement by modulating the gut and nutrient status. , live beneficial microorganisms, regulate immune by suppressing pro-inflammatory Th2 responses and bolstering Th1-mediated defenses, potentially reducing infection susceptibility through improved mucosal barrier function and balance. Immunonutrition, involving targeted supplementation with alongside nutrients like or omega-3 fatty acids, further amplifies activity and systemic immunity, particularly in vulnerable populations such as the elderly or patients, where it accelerates recovery and mitigates inflammatory overload.

Vaccination strategies

Vaccination strategies harness the immune system's ability to develop against pathogens by introducing safe antigens that trigger adaptive responses, including production and T-cell activation, without causing illness. This process establishes long-term protection through immunological , as discussed in foundational texts. Various types achieve this by presenting antigens in different forms, tailored to balance , , and ease of administration. Live-attenuated vaccines use weakened forms of the to replicate mildly in the body, closely mimicking natural and often inducing robust, long-lasting immunity with fewer doses. Examples include the measles-mumps-rubella (, which protects against three viral diseases and is administered in two doses during childhood. Inactivated vaccines, in contrast, contain killed that cannot replicate, providing safer options for immunocompromised individuals but typically requiring boosters for sustained protection; the inactivated (IPV), given as a series of shots, has nearly eradicated in vaccinated populations. Subunit vaccines target specific components, such as proteins, to elicit targeted responses without whole- risks; the human papillomavirus (HPV) vaccine, like Gardasil 9, uses virus-like particles from HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 to prevent cervical and other cancers. Emerging mRNA vaccines deliver genetic instructions for cells to produce antigens, enabling rapid production and strong immune activation; the Pfizer-BioNTech (BNT162b2), approved in 2020, demonstrated 95% efficacy against symptomatic in initial trials among individuals aged 16 and older. Achieving is a key goal of strategies, where sufficient coverage prevents to vulnerable groups. The threshold depends on the pathogen's (R₀), calculated as 1 - (1/R₀), representing the average secondary infections from one case in a susceptible . For , with an R₀ of 12–18, approximately 95% coverage is required to interrupt , protecting unvaccinated individuals through reduced community spread. Vaccine development follows rigorous phases to ensure safety and . Preclinical studies in labs and animals assess design and initial safety, followed by an (IND) application to the FDA for human trials. Phase I trials involve 20–100 volunteers to evaluate safety and dosage. Phase II expands to hundreds, testing and side effects across doses. Phase III engages thousands in randomized, placebo-controlled studies to confirm effectiveness against disease. Post-approval, phase IV monitors long-term effects. Adjuvants, such as aluminum salts or oil-in-water emulsions like MF59, are incorporated to enhance , boost and T-cell responses, reduce required doses, and improve in vulnerable populations like the elderly. Despite successes, vaccination faces challenges from anti-vaccine movements, which spread misinformation and erode trust, leading to hesitancy and outbreaks; the World Health Organization identified vaccine hesitancy as a top global health threat in 2019. Emerging pathogen variants, such as SARS-CoV-2 Omicron sublineages, can partially evade vaccine-induced antibodies, necessitating booster updates to maintain protection levels. For instance, while the original Pfizer mRNA vaccine showed 95% efficacy against early COVID-19 strains, effectiveness against variants like Delta was around 90% for severe disease prevention, underscoring the need for adaptive strategies.

Cancer immunotherapy

Cancer immunotherapy encompasses a range of strategies that leverage the immune system to target and eliminate malignant cells, transforming previously intractable tumors into manageable conditions through activation of adaptive and innate immune responses. These approaches address the immune system's natural capacity to recognize and destroy cancer cells, which is often suppressed in the , and have led to durable remissions in subsets of patients with advanced disease. Central to these therapies are tumor antigens, which serve as recognition targets for immune effectors. Neoantigens arise from tumor-specific somatic mutations, such as point mutations or insertions/deletions, creating novel peptides presented on (MHC) molecules to T cells; these are highly immunogenic due to their absence in normal tissues, making them ideal for personalized vaccines and T cell therapies. Cancer-testis antigens, conversely, are proteins normally restricted to germ cells and placental tissues but aberrantly expressed in various cancers due to epigenetic dysregulation, such as hypomethylation of promoter regions; examples include NY-ESO-1 and MAGE-A family members, which elicit + T cell responses while minimizing risks. Tumors evade immune detection through multiple mechanisms that disrupt and T cell function. Upregulation of programmed death-ligand 1 () on tumor cells, often induced by interferon-gamma from infiltrating T cells or oncogenic signaling via pathways like PI3K/AKT, binds PD-1 on T cells to inhibit activation and promote exhaustion, allowing tumor persistence. Loss of expression, achieved through genetic alterations (e.g., mutations in β2-microglobulin or genes) or epigenetic silencing, prevents neoantigen presentation to cytotoxic T cells, rendering tumors invisible to ; this occurs in approximately 30-40% of tumors and up to 90% in certain other cancers, such as colorectal , and contributes to resistance against T cell-based therapies. Checkpoint blockade inhibitors counteract evasion by restoring T cell activity. , a targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), was approved by the FDA in 2011 for unresectable or metastatic , blocking CTLA-4's inhibitory role in early T cell priming within lymph nodes; clinical trials demonstrated objective response rates of 10-15%, with durable responses in 20-40% of responders leading to long-term survival benefits. Chimeric antigen receptor (CAR) T cell therapies engineer patient T cells to express synthetic receptors targeting tumor s, building on principles of . Axicabtagene ciloleucel (Yescarta), a CD19-directed CAR-T product, received FDA approval in 2017 for relapsed or large after at least two prior therapies; in the pivotal ZUMA-1 trial, it achieved an overall response rate of 82% and complete remission in 54% of patients, with many maintaining responses beyond two years. Bispecific antibodies engage immune cells directly against tumors by simultaneously binding tumor antigens and immune receptors. Blinatumomab (Blincyto), a CD19/CD3 bispecific T cell engager, was granted accelerated FDA approval in 2014 and full approval in 2017 for relapsed or refractory B-cell precursor ; it redirects T cells to lyse + tumor cells, yielding complete remission rates of 40-45% in heavily pretreated adults.

Evolutionary Perspectives

Origins and development in vertebrates

The immune system in vertebrates exhibits remarkable diversity, with adaptive immunity emerging independently in jawless and jawed lineages. In jawless vertebrates, such as lampreys and , adaptive immune recognition relies on variable lymphocyte receptors (VLRs) rather than immunoglobulins (Igs) or T-cell receptors (TCRs). These VLRs are (LRR)-based proteins that undergo somatic diversification through a RAG-independent mechanism involving gene conversion with flanking LRR cassettes, enabling antigen-specific responses with affinities comparable to those of mammalian antibodies. Lymphocytes expressing VLRA and VLRB mature in specialized tissues like the supraneural body and typhlosole, analogous to lymphoid organs in jawed vertebrates. The transition to jawed vertebrates (gnathostomes), which appeared around 500 million years ago, introduced a fundamentally different adaptive immune system based on RAG1 and RAG2 genes that mediate V(D)J recombination. This process assembles diverse variable (V), diversity (D), and joining (J) gene segments to generate a vast repertoire of Igs and TCRs, allowing for precise antigen recognition and memory. IgM represents the primordial antibody class in gnathostomes, with its heavy- and light-chain genes organized in clusters in early-diverging groups like cartilaginous fish, facilitating initial humoral responses before the evolution of class-switched isotypes. Lymphoid organs in vertebrates evolved to support development and maturation, with the and playing central roles. The originates from epithelial buds at the base of the arches, specifically from the ectoderm-endoderm junction in the pharyngeal pouches of , where it differentiates into a site for T-cell shortly after hatching. In teleosts like , thymic buds form above the first few arches, with and vascular elements immigrating from to establish the organ's structure. The , emerging as the earliest secondary lymphoid organ in gnathostomes, features a white pulp region for adaptive responses, evolving from basic B-cell zones around arterioles in cartilaginous to more segregated T- and B-cell compartments in bony and higher vertebrates. This diversification of the vertebrate immune system was driven by co-evolution with pathogens, where selective pressures from diverse microbial threats promoted the expansion of receptor repertoires and organ complexity over hundreds of millions of years. In gnathostomes, the integration of innate and adaptive components enhanced defense against evolving pathogens, fostering genetic mechanisms like V(D)J recombination to generate variability far exceeding that of germline-encoded innate receptors.

Invertebrate immune mechanisms

Invertebrates lack an and rely exclusively on innate immune mechanisms to defend against pathogens and parasites. These responses are germline-encoded and evolutionarily ancient, providing rapid but non-specific protection through cellular and humoral pathways. Hemocytes, the circulating immune cells in many such as and crustaceans, play a central role in cellular immunity by recognizing and engulfing invading microbes via phagocytosis.00128-6) In like the mosquito Anopheles gambiae, phagocytic hemocytes actively internalize and parasites, initiating downstream processes. This mechanism is modulated by signaling molecules, such as in lepidopteran , which enhances hemocyte phagocytic activity through D1-like receptors. Humoral immunity in invertebrates often involves the prophenoloxidase (proPO) system, which activates to produce for encapsulation and killing. Phenoloxidase enzymes, activated by a cascade of serine proteases in response to pathogen-associated molecular patterns, oxidize into quinones that polymerize into , trapping and immobilizing invaders.00108-7) This melanization process is prominent in arthropods, where it contributes to and defense against fungi, , and parasites, as seen in like the greater wax moth . (RNAi) serves as a key antiviral mechanism in both and animal by targeting viral genomes. Animal also employ and for intracellular control.01029-5) degrades engulfed pathogens within hemocytes or other cells, promoting survival against and viruses in models like the fruit fly and nematode . , meanwhile, eliminates infected cells to limit spread, balancing with to maintain during . Social insects extend innate immunity through collective behaviors known as social immunity, where colony members cooperate to reduce disease transmission. In ant colonies, such as those of the Camponotus pennsylvanicus, trophallaxis—the exchange of regurgitated food—spreads compounds and prophylactic agents, enhancing nestmate resistance to pathogens like Metarhizium anisopliae. employ grooming and allogrooming to remove parasites from nestmates, as observed in species like Reticulitermes flavipes, where physical removal and antiseptic secretions collectively suppress fungal infections.01503-5) These behaviors function as an extended immune system at the colony level, compensating for the vulnerability arising from high-density living. Unlike vertebrates, immune responses exhibit no classical immunological , but evidence supports transgenerational immune priming, where prior exposure enhances resistance through epigenetic modifications. In insects like the Tribolium castaneum, parental infection induces and changes that upregulate genes in progeny, improving survival against the same . This priming is context-specific and heritable across generations, as demonstrated in bumblebees () exposed to bacterial challenges. Such mechanisms represent an evolutionary precursor to adaptive immunity in vertebrates.00128-6)

Pathogen evasion strategies

Pathogens have evolved sophisticated mechanisms to evade immune responses, allowing them to persist, replicate, and cause disease. These strategies target both innate and adaptive immunity, often by exploiting or subverting normal cellular processes. By hiding from immune detection, modulating immune signaling, or rapidly altering surface antigens, microbes can avoid clearance and establish chronic infections. One prominent evasion tactic is intracellular hiding, where sequester themselves within cells or structures to avoid extracellular immune surveillance. For instance, establishes latency by integrating its genome into the DNA of resting + T cells, rendering infected cells transcriptionally silent and invisible to cytotoxic T lymphocytes. This reservoir formation enables long-term persistence despite antiretroviral . Similarly, induces the formation of granulomas in the lungs, walled-off structures composed of immune cells that contain but do not eradicate the bacteria, allowing dormancy and reactivation under favorable conditions. Pathogens also directly modulate immune responses to dampen host defenses. Viruses like cause profound by infecting immune cells such as lymphocytes and dendritic cells, leading to reduced production and impaired T cell activation, which increases susceptibility to secondary infections. In bacteria, produces , a surface protein that binds the Fc region of IgG antibodies, preventing opsonization and while potentially redirecting antibodies away from the bacterial surface. Antigenic variation further enables evasion by altering pathogen surface molecules recognized by antibodies and T cells. Influenza viruses employ antigenic drift through gradual mutations in hemagglutinin and neuraminidase genes, and antigenic shift via reassortment of genome segments from different strains, both reducing the effectiveness of pre-existing immunity. The protozoan parasite Trypanosoma brucei, causative agent of African sleeping sickness, uses variant surface glycoprotein (VSG) switching, rapidly changing its coat protein expression from a repertoire of over 1,000 genes to evade antibody responses.30152-5) Recent insights from the pandemic highlight ongoing pathogen adaptations. The viral inhibits type I (IFN) signaling by binding to host receptors and blocking downstream pathways, thereby blunting innate antiviral responses and allowing unchecked replication in early infection stages. Paradoxically, can also induce a hyperinflammatory , characterized by excessive release of pro-inflammatory cytokines like IL-6 and TNF-α, which overwhelms the immune system and contributes to severe tissue damage.

Historical Development

Early discoveries

The practice of , an early form of against , originated in during the tenth century, where dried smallpox scabs were inhaled or inserted into the skin to induce a mild and confer . This technique spread to other regions, including the , and was introduced to England in 1718 by , who observed it during her time in and had her own children inoculated to demonstrate its efficacy. reduced smallpox mortality but carried risks, as it sometimes led to full-blown disease in recipients. In 1796, English physician Edward Jenner advanced immunization by developing the first vaccine, using cowpox—a milder related virus—to protect against smallpox. Jenner observed that milkmaids exposed to cowpox appeared immune to smallpox and tested this by inoculating an 8-year-old boy, James Phipps, with pus from a cowpox lesion on dairymaid Sarah Nelmes, followed by a later exposure to smallpox material, which failed to cause illness. He published his findings in 1798, coining the term "vaccine" from the Latin for cowpox (vacca), establishing a safer alternative to variolation that became widely adopted. During the 1880s, Russian-born zoologist identified phagocytosis as a key mechanism of immune defense while studying starfish larvae in , , where he observed mobile cells engulfing foreign particles. Extending his observations to vertebrates, Metchnikoff proposed that specialized , or , actively consume and destroy invading microbes, forming the basis of cellular immunity. His work, recognized with the 1908 Nobel Prize in Physiology or shared with , highlighted innate immune responses independent of antibodies. In 1890, German bacteriologist , collaborating with Shibasaburo Kitasato, discovered antitoxins in the blood of animals immunized against , demonstrating that these substances could neutralize the disease's and treat infected individuals. By injecting from recovered animals into patients, von Behring's therapy dramatically lowered mortality rates, marking the first successful use of . This breakthrough earned him the inaugural 1901 in Physiology or Medicine and paved the way for concepts. These empirical discoveries laid foundational observations that later informed key immunological theories.

Key immunological theories

Paul Ehrlich's side-chain theory, proposed in 1897, represented an early attempt to explain the specificity of immune responses at the cellular level. Ehrlich postulated that s possess pre-formed receptor molecules, termed "side-chains," on their surfaces that function like locks fitting specific or keys. Upon binding, these side-chains are released into the bloodstream as antitoxins, neutralizing the invader, while the cell regenerates additional side-chains to replenish its receptors. This mechanism accounted for both the specificity of - interactions and the amplification of immune responses through increased receptor production. The theory laid foundational groundwork for understanding receptor-ligand interactions in and served as a precursor to later concepts of by emphasizing pre-existing cellular specificity rather than instructional models of antibody formation. Building on such ideas, Frank Macfarlane Burnet formalized the in his 1959 monograph, providing a comprehensive framework for adaptive immunity. The theory posits that the immune system comprises a diverse population of pre-committed clones, each bearing unique receptors specific to particular , generated randomly during development. encounter selects and activates the matching clone, triggering its and into effector cells, such as plasma cells producing , while also generating memory cells for enhanced secondary responses. This process explains the specificity, diversity, and memory of immune responses, with self-tolerance achieved through the elimination of autoreactive clones during . Burnet's model resolved debates over synthesis by rejecting template-based instruction in favor of germline-encoded variability, profoundly influencing modern . In parallel, Peter Medawar's work in the 1940s elucidated the concept of acquired immunological , demonstrating how the immune system could be rendered unresponsive to specific antigens under certain conditions. Through experiments with grafts in mice, Medawar and colleagues showed that injecting foreign cells into newborn animals induced a state of , allowing subsequent grafts from the same donor to be accepted without rejection. This phenomenon, observed in dizygotic twin naturally tolerant to each other's blood cells due to fetal exchanges, highlighted that arises from early antigenic exposure before immune maturity, preventing the development of reactive clones. Medawar's findings, which earned him the 1960 shared with Burnet, provided critical insights into self-nonself discrimination and paved the way for by revealing mechanisms to suppress allograft rejection. Charles Janeway's 1989 proposal revived interest in innate immunity by integrating it with adaptive responses through the theory. Janeway argued that the immune system distinguishes infectious nonself from noninfectious self via germline-encoded receptors on innate immune cells that detect conserved microbial patterns, rather than relying solely on the adaptive arm's antigen-specific recognition. These pattern recognition receptors, later identified as Toll-like receptors, provide initial signals to activate antigen-presenting cells, delivering costimulatory cues essential for adaptive immunity. This framework challenged the adaptive-centric view dominant since the mid-20th century, emphasizing innate immunity's evolutionary primacy and its role in priming T and B cell responses, thus reshaping immunological paradigms.

Modern advancements

The completion of the in 2003 marked a pivotal advancement in understanding the immune system by providing a complete reference sequence of the , enabling the systematic identification and annotation of genes involved in immunity. This effort cataloged approximately 20,000 protein-coding genes, among which around 1,500 are associated with immune functions, including the 10 (TLR) genes that play a central role in innate immune recognition of pathogens. following the project revealed extensive evolutionary diversity, with over 1,700 intact TLR sequences identified across vertebrate species, highlighting adaptations in immune sensing mechanisms. These discoveries facilitated targeted studies on immune gene regulation and variation, laying the groundwork for personalized . In the 2010s, single-cell RNA sequencing (scRNA-seq) emerged as a transformative technology for dissecting immune cell heterogeneity, allowing researchers to profile transcriptomes at the resolution of individual cells rather than bulk populations. This approach uncovered previously unrecognized subsets within immune cell types, such as diverse activation states in T cells and macrophages during or , revealing dynamic heterogeneity that bulk sequencing obscured. Seminal applications in demonstrated how scRNA-seq could map rare immune populations and their responses in health and disease, enhancing understanding of adaptive immune diversity and tissue-specific adaptations. The development of CRISPR-Cas9 gene editing in 2012 revolutionized immune system manipulation by enabling precise, efficient modifications to immune cells, including the creation of universal donor cells for therapies. By targeting genes like those encoding ( and II molecules, researchers engineered allogeneic T cells and stem cells that evade host immune rejection, reducing risks in transplantation and . This technology has been applied to enhance CAR-T cell therapies, where multiplex editing knocks out inhibitory receptors and inserts antigen-specific receptors, improving efficacy against tumors while minimizing off-target effects. Advancements in during the 2020s have integrated into immunogenicity prediction, exemplified by tools like NetMHCpan-4.1, which uses neural networks to forecast peptide-MHC binding affinities with high accuracy across diverse HLA alleles. These AI-driven models analyze epitope sequences to predict T-cell immunogenicity, accelerating vaccine and therapeutic design by identifying immunogenic candidates without extensive wet-lab validation. Such predictions have proven instrumental in neoantigen targeting for personalized cancer vaccines, achieving up to 90% accuracy in binding affinity forecasts for novel peptides. The advent of mRNA vaccines represented a in immune system modulation, particularly demonstrated by their rapid deployment against in , which elicited robust humoral and cellular responses through transient expression of antigens in host cells. Unlike traditional vaccines, mRNA platforms allow swift to emerging pathogens via modifications, bypassing lengthy processes and enabling tunable immune activation via delivery. This technology has expanded to therapeutic applications, such as in situ cancer vaccines that encode tumor antigens to prime antitumor immunity, underscoring its versatility in harnessing innate and adaptive responses. From 2023 to 2025, saw further progress in , with enhanced strategies for tumor immune escape and personalized treatments, as well as the 2025 in Physiology or Medicine awarded for discoveries in peripheral immune regulation mechanisms that complement central tolerance.

References

  1. [1]
    Overview of the Immune System | NIAID
    Dec 30, 2013 · The overall function of the immune system is to prevent or limit infection. All immune cells come from precursors in the bone marrow and ...
  2. [2]
    The components of the immune system - Immunobiology - NCBI - NIH
    The cells of the immune system originate in the bone marrow, where many of them also mature. They then migrate to guard the peripheral tissues, ...1-1. The white blood cells of... · 1-3. The peripheral lymphoid...
  3. [3]
    In brief: How does the immune system work? - InformedHealth.org
    Jun 6, 2023 · The immune system has a vital role: It protects your body from harmful substances, germs and cell changes that could make you ill.
  4. [4]
    In brief: The innate and adaptive immune systems - NCBI - NIH
    Aug 14, 2023 · The immune system fights germs on the skin, in the tissues of the body, and in bodily fluids such as blood. It is made up of the innate (general) ...Protection offered by immune... · The adaptive immune system... · cells
  5. [5]
    In brief: What are the organs of the immune system? - NCBI - NIH
    Aug 14, 2023 · Primary lymphoid organs: These organs include the bone marrow and the thymus. · Secondary lymphoid organs: These organs include the lymph nodes, ...Missing: count | Show results with:count
  6. [6]
    Immunity In Depth | Linus Pauling Institute | Oregon State University
    The immune system is broadly divided into two major components: innate immunity and adaptive immunity. Innate immunity involves immediate, nonspecific responses ...
  7. [7]
    Physiology, Immune Response - StatPearls - NCBI Bookshelf - NIH
    Primary lymphoid organs (thymus and bone marrow): These are the sites where T and B cells first express antigen receptors and mature functionally. Secondary ...
  8. [8]
    Parts of the Immune System | Children's Hospital of Philadelphia
    Organs and tissues important to the proper functioning of the immune system include the thymus and bone marrow, lymph nodes and vessels, spleen, and skin.Missing: leukocytes | Show results with:leukocytes
  9. [9]
    WBC count: MedlinePlus Medical Encyclopedia
    Mar 2, 2025 · Normal Results​​ The normal number of WBCs in the blood is 4,500 to 11,000 WBCs per microliter (4.5 to 11.0 × 109/L). Normal value ranges may ...
  10. [10]
    Histology, White Blood Cell - StatPearls - NCBI Bookshelf
    Nov 14, 2022 · Leukocytes can be classified as granulocytes and agranulocytes based on the presence and absence of microscopic granules in their cytoplasm.
  11. [11]
    Definition of leukocyte - NCI Dictionary of Cancer Terms
    Types of leukocytes are granulocytes (neutrophils, eosinophils, and basophils), monocytes, and lymphocytes (T cells and B cells). Checking the number of ...
  12. [12]
    Understanding the evolution of immune genes in jawed vertebrates
    Driven by co‐evolution with pathogens, host immunity continuously adapts to optimize defence against pathogens within a given environment.
  13. [13]
    https://www.jacionline.org/article/S0091-6749(09)01083-5/fulltext
  14. [14]
    An introduction to immunology and immunopathology
    Sep 12, 2018 · Beyond structural and chemical barriers to pathogens, the immune system has two fundamental lines of defense: innate immunity and adaptive ...
  15. [15]
    The Dynamics of the Skin's Immune System - PMC - PubMed Central
    The stratum corneum is composed of three layers and it is both an outside‒in barrier to prevent the entry of foreign substances and microorganisms, and an ...
  16. [16]
    Epidermal tight junctions in health and disease - PMC
    The epidermis has 2 major barrier structures: stratum corneum, the outmost layer and tight junctions, intercellular junctions that seal adjacent keratinocytes ...
  17. [17]
    Innate immune system - Autoimmunity - NCBI Bookshelf - NIH
    Innate immunity is comprised of different components including physical barriers (tight junctions in the skin, epithelial and mucous membrane surfaces, mucus ...Missing: keratin | Show results with:keratin
  18. [18]
    Host Defenses, Immunodeficiencies, and Autoimmune Disorders
    Physical barriers play an important role in preventing microbes from reaching tissues that are susceptible to infection. At the cellular level, barriers consist ...
  19. [19]
    Ocular Surface as Barrier of Innate Immunity - PMC - PubMed Central
    May 15, 2015 · This paper will review the anatomical and physiological aspects of the cornea, conjunctiva and lacrimal apparatus, as well as the innate immunity at the ocular ...
  20. [20]
    The blood-brain barrier: an engineering perspective - PMC
    Aug 30, 2013 · Here we reconstruct the structure, function, and transport properties of the blood-brain barrier from an engineering perspective.
  21. [21]
    Applications of Lysozyme, an Innate Immune Defense Factor, as an ...
    Due to its capacity to disrupt the bacterial cell wall, lysozyme has been considered as an endogenous antibiotic, innately essential in the defense against ...
  22. [22]
    Epithelial antimicrobial defence of the skin and intestine - PMC - NIH
    Cathelicidins also typically kill microorganisms through membrane disruption. Like the defensins, cathelicidins are usually cationic, α-helical peptides ...
  23. [23]
    The role of gastric acid in preventing foodborne disease and how ...
    The secretion of hydrochloric acid by the stomach plays an important role in protecting the body against pathogens ingested with food or water.
  24. [24]
    The Biology of Lactoferrin, an Iron-Binding Protein That Can Help ...
    One of the most well-known characteristics of LF is that it is antibacterial (19, 144–148), antiviral (99, 149–151), antifungal (152–154), anti-inflammatory (26) ...
  25. [25]
    The Role of Surfactant in Lung Disease and Host Defense against ...
    Pulmonary surfactant is essential for life as it lines the alveoli to lower surface tension, thereby preventing atelectasis during breathing.
  26. [26]
    An Overview of Pathogen Recognition Receptors for Innate ... - NIH
    Pathogen recognition receptors (PRRs) are a class of germ line-encoded receptors that recognize pathogen-associated molecular patterns (PAMPs).
  27. [27]
    Pattern recognition receptors: function, regulation and therapeutic ...
    Jul 11, 2025 · This review examines the classification, structure, and signaling cascades of key PRR families, including toll-like receptors (TLRs), C-type ...
  28. [28]
    Pattern recognition receptors in health and diseases - Nature
    Aug 4, 2021 · Pattern recognition receptors (PRRs) are a class of receptors that can directly recognize the specific molecular structures on the surface of pathogens.
  29. [29]
    https://doi.org/10.1016/j.cell.2006.02.015
  30. [30]
    https://doi.org/10.1093/intimm/dxp017
  31. [31]
    Overview of the Immune Response - PMC - PubMed Central
    This overview identifies key mechanisms used by the immune system to respond to invading microbes and other exogenous threats
  32. [32]
    Monocytes and Macrophages Regulate Immunity through Dynamic ...
    Monocyte life span is determined by the integration of a complex network of survival and death signals [36]. In monocytes, a constitutively active cell death ...Monocytes: Emerging Roles Of... · Monocytes/macrophages And... · Monocyte And Macrophage Cell...
  33. [33]
    Neutrophils—From Bone Marrow to First-Line Defense of the Innate ...
    Neutrophils (polymorphonuclear cells; PMNs) form a first line of defense against pathogens and are therefore an important component of the innate immune ...
  34. [34]
    Innate and Adaptive Immune Cells: General Introduction - NCBI - NIH
    Macrophages have a number of important functions in body defenses such as (1) capture by phagocytosis and intracellular killing of microorganisms; (2) ...
  35. [35]
    The Forgotten Innate Immune Cells: Unraveling Their Prospective ...
    Jun 24, 2025 · Key players—monocytes/macrophages, neutrophils, and dendritic cells—identify and eliminate invaders through processes such as phagocytosis.
  36. [36]
    Comprehensive snapshots of natural killer cells functions, signaling ...
    Nov 8, 2024 · Derived from a common lymphoid progenitor, they lack CD3, B-cell, or T-cell receptors but wield high cytotoxicity via perforin and granzymes. NK ...
  37. [37]
    NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in ... - NIH
    Instead, mature NK cells reserve large amounts of cytotoxic granules containing perforin and granzymes ... This review focuses on NK cell-mediated anti-tumor ...
  38. [38]
    Human natural killer cells: form, function, and development - NIH
    Human natural killer (NK) cells are innate lymphoid cells that mediate important effector functions in the control of viral infection and malignancy.
  39. [39]
    ADCC: the rock band led by therapeutic antibodies, tumor and ... - NIH
    Apr 16, 2025 · The key agents of ADCC are natural killer (NK) cells, specifically targeting antibody-covered cancer cells through the CD16 receptor. While ...
  40. [40]
    Eosinophils in innate immunity: an evolving story - PMC
    Eosinophils are innate immune granulocytes best recognized for their cytotoxic effector functions, causing damage to parasitic pathogens in helminth infections, ...<|control11|><|separator|>
  41. [41]
    IgE, Mast Cells, Basophils, and Eosinophils - PMC - PubMed Central
    Mast cells, basophils, and eosinophils are central effector cells in allergic inflammation, as well as in innate and adaptive immunity.
  42. [42]
    Roles of mast cells and basophils in innate and acquired immunity
    Host defense against parasites. Parasite infections are often associated with increased levels of circulating basophils and eosinophils, markedly increased ...
  43. [43]
    Innate Immunity and its Regulation by Mast Cells - PMC
    This review discusses the evidence supporting the dual role of MCs, both as sentinels for invading pathogens, as well as regulatory cells throughout the course ...
  44. [44]
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993766/
  45. [45]
    The complement system and innate immunity - Immunobiology - NCBI
    The complement system, part of innate immunity, uses plasma proteins to opsonize pathogens, induce inflammation, and mark them for destruction by phagocytes.
  46. [46]
    Once upon a time, inflammation - PMC - PubMed Central
    Disturbance of function (functio laesa): the legendary fifth cardinal sign of inflammation, added by Galen to the four cardinal signs of Celsus. Bull N Y ...
  47. [47]
    Role of Interleukin 10 Transcriptional Regulation in Inflammation ...
    IL-10 is a potent anti-inflammatory cytokine that limits immune response, preventing damage and maintaining tissue homeostasis. It is crucial for preventing ...
  48. [48]
    Neutrophil Apoptosis: Relevance to the Innate Immune Response ...
    Neutrophil apoptosis is a programmed cell death that conserves toxic contents, helps resolve inflammation, and has anti-inflammatory effects.
  49. [49]
    The complement system - PMC - NIH
    The three different pathways of complement activation: alternative, classical and lectin pathways; factors that can inhibit the pathways are indicated in boxes ...
  50. [50]
    The complement system: history, pathways, cascade and inhibitors
    Complement mediates responses to inflammatory triggers through a co-ordinated sequential enzyme cascade leading to clearance of foreign cells through pathogen ...Lectin Pathway · Complement Cascade · Inherent Regulation Of...
  51. [51]
    Regulation of the Complement System by Pentraxins - PMC
    Aug 2, 2019 · The central players in the humoral arm of innate immunity include complement (C) system components and soluble pattern recognition molecules, ...
  52. [52]
    Regulation of Complement and Contact System Activation via C1 ...
    Oct 26, 2016 · The serpin C1 inhibitor (C1-INH) is the only regulator of classical complement activation as well as the major regulator of the contact system.
  53. [53]
    Molecular mechanisms that control expression of the B lymphocyte ...
    The B cell receptor for antigen (BCR) is a complex of membrane immunoglobulin (mIg) and at least two other proteins, Ig alpha (mb-1) and Ig beta (B29).<|control11|><|separator|>
  54. [54]
    αβ and γδ T cell receptors: Similar but different - PubMed
    There are 2 populations of T lymphocytes, αβ T and γδ T cells, that can be distinguished by the expression of either an αβ TCR or a γδ TCR, respectively.
  55. [55]
    The clonal selection theory of acquired immunity - Internet Archive
    Sep 11, 2008 · The clonal selection theory of acquired immunity. by: Burnet, F. M. (Frank Macfarlane), Sir, 1899-1985. Publication date: 1959. Topics: Immunity ...
  56. [56]
    [PDF] Susumu Tonegawa - Nobel Lecture
    Recombination Rule. The joining of V-J or V-D-J involves a site-specific recombination. It might therefore be expected that these gene segments would carry ...
  57. [57]
    Role of recombination activating genes in the generation of antigen ...
    V(D)J recombination ... The junctional diversification can expand the diversity upto 1011 from the earlier 106 through the combinatorial diversification.
  58. [58]
    Impact of new sequencing technologies on studies of the human B ...
    ... V(D)J recombination, which together with heavy and light chain pairing ... 1011 different antibody specificities [2]. Somatic hypermutation, a fourth ...
  59. [59]
    The thymus and central tolerance - PMC
    Central tolerance occurs mainly in the medullary region of the thymus and depends upon contact with peptide-MHC complexes expressed on bone-marrow-derived ...
  60. [60]
    Positive and negative selection shape the human naive B cell ... - JCI
    Nov 23, 2021 · A central tolerance checkpoint occurs in the bone marrow and removes the vast majority of self-reactive immature B cells that express ...
  61. [61]
    Present Yourself! By MHC Class I and MHC Class II Molecules - PMC
    Nov 1, 2017 · This is a story of proteases and MHC-like chaperones that support the MHC class I and II molecules in presenting peptides to the immune system.
  62. [62]
    The ins and outs of MHC class II-mediated antigen processing and ...
    In this Review, we describe our current knowledge of the mechanisms of uptake and processing of antigens, the intracellular formation of peptide–MHC class II ...
  63. [63]
    Cross-presentation of exogenous antigens on MHC I molecules - PMC
    This pathway plays key roles in antimicrobial and antitumor immunity, and also immune tolerance. Recent advances have broadened our understanding of the ...
  64. [64]
    What the HLA-I!—Classical and Non-classical HLA Class I and Their ...
    Dec 9, 2019 · This review focuses on the current understanding of the non-classical HLA-I subtypes: HLA-E, HLA-F and HLA-G, within and outside the field of type 1 diabetes.
  65. [65]
    CD4+T Cells: Differentiation and Functions - PMC - PubMed Central
    CD4+T cells are crucial for immune response, activated by antigen-MHC, and differentiate into subtypes like Th1, Th2, Th17, and regulatory T cells. They ...
  66. [66]
    A two-step, two-signal model for the primary activation of precursor ...
    I present here a new model for the primary activation of precursor helper T cells. Observations demonstrate that the immune system learns not to respond to ...Missing: review | Show results with:review
  67. [67]
    The B7/CD28/CTLA4 T-Cell Activation Pathway
    Jan 3, 2000 · This model proposes that T-cell activation requires two independent signals. The first is transduced through the T-cell receptor (TCR) after ...Missing: paper | Show results with:paper
  68. [68]
    Fas/FasL and perforin–granzyme pathways mediated T cell cytotoxic ...
    In this study, we evaluated the cytotoxic T cell responses involving two independently functioning but complementary mechanisms: Fas–Fas ligand and perforin– ...
  69. [69]
    Cytotoxic CD8 + T cells in cancer and cancer immunotherapy - Nature
    Sep 15, 2020 · Granulysin and perforin subsequently create pores in the endosomal membrane and release several granzymes into the cytoplasm. In addition, Fas ...Cd8 T Cells · Cd8 T-Cell (car T-Cell)... · The Tme And Immune-Escape...
  70. [70]
    Cytotoxic T lymphocyte perforin and Fas ligand working in concert ...
    The fast-acting mechanism is believed to involve secreted perforin, which forms 'pores' in the target membrane through which co-secreted granzymes somehow enter ...
  71. [71]
    CD4 T Helper Cell Subsets and Related Human Immunological ...
    Oct 28, 2020 · Among the CD4 T subsets possessing helper functions (Figure 1), Th1 cells induce type 1 responses to protect against intracellular pathogens ...
  72. [72]
    Heterogeneity and plasticity of T helper cells | Cell Research - Nature
    Dec 15, 2009 · CD4 T helper (Th) cells play critical roles in adaptive immune responses. They recruit and activate other immune cells including B cells, ...
  73. [73]
    Regulatory T Cells, Transforming Growth Factor–β, and Immune ...
    Active immune suppression is critical for establishing self-tolerance, controlling inflammatory responses, and maintaining immune homeostasis. Naturally ...
  74. [74]
    A Duet by Transforming Growth Factor-β and Interleukin-10: Immunity
    TGF-β1 and IL-10 are regulatory cytokines. TGF-β1 targets T cells for tolerance, while IL-10 limits immune responses to microbial antigens.
  75. [75]
    γδ T cells: origin and fate, subsets, diseases and immunotherapy
    Nov 22, 2023 · While γδ T cells act independently of MHC restriction, the activation of NK cells is intimately regulated by receptors which sense ...
  76. [76]
    Human γδ T-Cell Control of Mucosal Immunity and Inflammation - NIH
    May 7, 2018 · γδ T-cell detection of stress molecules and microbial signals can significantly alter adaptive immunity and inflammation at mucosal barrier sites.
  77. [77]
    Functions of Antibodies - PMC - PubMed Central - NIH
    Examples of antibody functions include neutralization of infectivity, phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and complement-mediated ...
  78. [78]
    The Continuing Story of T-cell Independent Antibodies - PMC - NIH
    The purpose of this article is to review the role of extrafollicular and T-cell independent antibody responses in humoral immunity.
  79. [79]
    T-independent antigen induces humoral memory through germinal ...
    Jan 12, 2022 · T-dependent humoral responses generate long-lived memory B cells and plasma cells (PCs) predominantly through germinal center (GC) reaction.Introduction · Results and discussion · Concluding remarks · Materials and methods
  80. [80]
    The structure of a typical antibody molecule - Immunobiology - NCBI
    Each IgG molecule consists of two heavy chains and two light chains. The two heavy chains are linked to each other by disulfide bonds and each heavy chain is ...
  81. [81]
    The distribution and functions of immunoglobulin isotypes - NCBI - NIH
    Immunoglobulin isotypes are selectively distributed in the body. IgG and IgM predominate in plasma, whereas IgG and monomeric IgA are the major isotypes in ...
  82. [82]
    Understanding IgM Structure and Biology to Engineer New Antibody ...
    Apr 16, 2025 · In this review, we summarize the recent advances in the knowledge of IgM biogenesis and structure and discuss the therapeutic opportunities of IgM over IgG.
  83. [83]
    Fc-dependent antibody effector functions in SARS-CoV-2 infection
    Dec 19, 2022 · Antibody-dependent complement deposition​​ Complement is a highly conserved component of the immune system that functions by opsonizing pathogens ...
  84. [84]
    Strategies to guide the antibody affinity maturation process - PMC
    Affinity maturation increases antibody activity through multiple rounds of somatic hypermutation and selection in the germinal center.
  85. [85]
    GERMINAL CENTER B CELL DYNAMICS - PMC - NIH
    Affinity maturation selects for SHM variants with increased affinity for HEL3X but which now also bind a quadruple mutant HEL4X. When this experiment is ...
  86. [86]
    A guide to adaptive immune memory | Nature Reviews Immunology
    Jun 3, 2024 · The ability of T cells and B cells to form memory cells after antigen exposure is the rationale behind vaccination. Understanding immune memory ...
  87. [87]
    Immunological memory - Immunobiology - NCBI Bookshelf
    The distinction between primary and secondary antibody responses is most clearly seen in those cases where the primary response is dominated by antibodies ...
  88. [88]
    Memory B cells | Nature Reviews Immunology
    Jul 3, 2023 · In autoimmune settings, there is also increasing evidence that memory B cells are the direct precursors of plasma cells that produce pathogenic ...
  89. [89]
    Epigenetic Regulation of T Cell Memory - ScienceDirect.com
    Epigenetic imprinting is central to the formation and maintenance of memory in T cells and reflects the conditions of primary T cell activation.
  90. [90]
    Booster dose of mRNA vaccine augments waning T cell and ...
    Our results indicate that the 3rd vaccination fosters antibody and T cell immune response independently from vaccine type used for the first two injections.
  91. [91]
    The interplay of thyroid hormones and the immune system
    Here, T3 and T4 were described to directly regulate various functional aspects including activation, differentiation, proliferation and/or migration. Moreover, ...
  92. [92]
    The anti-inflammatory and immunosuppressive effects of ...
    Notably, glucocorticoids repress transcription of many genes encoding pro-inflammatory cytokines and chemokines, cell adhesion molecules and key enzymes ...
  93. [93]
    Pleiotropic Effects of Glucocorticoids on the Immune System in ...
    Thus, these molecules induced by GCs attenuate inflammation by inhibiting NF-κB and MAPK cascades. Furthermore, NF-κB and GR might cooperatively control gene ...
  94. [94]
    Catecholamines modulate human NK cell circulation and function ...
    Increases in catecholamines have been shown to induce changes in migration of lymphocytes, in particular NK cells. To analyze the mechanisms of catecholamine- ...
  95. [95]
    Gender-Specific Impact of Sex Hormones on the Immune System - NIH
    Mar 27, 2023 · This study summarizes the available evidence regarding the physiological effects of sex hormones on human immune cell function and the underlying biological ...
  96. [96]
    Sex differences in immune responses | Nature Reviews Immunology
    Aug 22, 2016 · Because sex steroids profoundly affect the immune response, it is not surprising that hormonal changes during the female menstrual cycle ...
  97. [97]
    Sex hormone signaling and regulation of immune function
    Nov 14, 2023 · Sex steroids, including estrogens, androgens, and progestins, have profound effects on immune function.
  98. [98]
    thyroid hormone-mediated modulation of lymphocyte activity through ...
    ... T3 is the thyroid hormone responsible for regulating lymphocyte activity. On the other hand, hyperthyroid mice showed high serum levels of T3 and T4, with ...
  99. [99]
    Regulation of the Hypothalamic-Pituitary-Adrenal Axis by Cytokines
    This article reviews published findings that have documented which cytokines have been shown to influence hormone secretion from the HPA axis.
  100. [100]
    Immune Modulation of the Hypothalamic-Pituitary-Adrenal (HPA ...
    In examining the effects of cytokines on HPA axis function, the innate proinflammatory cytokines—IL-1, IL-6, and TNFα—have been the most studied. However, other ...
  101. [101]
    Wound Healing Phases - StatPearls - NCBI Bookshelf
    The inflammatory phase begins with hemostasis and chemotaxis. Both the white cells and thrombocytes speed up the inflammatory process by releasing more ...
  102. [102]
    Principles of Wound Healing - Mechanisms of Vascular Disease
    Cellular and molecular events during normal wound healing progress through four major, integrated, phases of haemostasis, inflammation, proliferation and ...
  103. [103]
    Recent advances in molecular mechanisms of skin wound healing ...
    The healing process is comprised of several stages of proliferation, inflammation, hemostasis, and remodeling, which occur in a coordinated manner (36).
  104. [104]
    The emerging role of tissue regulatory T cells in tissue repair and ...
    Treg cells not only suppress immune responses but also promote tissue repair by secreting pro-repair mediators.
  105. [105]
    Cellular and Molecular Processes in Wound Healing - MDPI
    During the proliferative phase, macrophages play a particularly important role in angiogenesis, as they position themselves around the newly formed blood ...
  106. [106]
    Interplay between mesenchymal stem cells and macrophages - NIH
    The cross-talk between MSCs and macrophages plays a crucial role in regulating the immune system and in promoting tissue regeneration.
  107. [107]
    The physiology of wound healing - ScienceDirect
    This process of wound healing is divided into four distinct phases: haemostasis, inflammation, proliferation and tissue remodelling.
  108. [108]
    Regeneration or scarring: An immunologic perspective - Harty - 2003
    Jan 14, 2003 · Complete regeneration of complex tissues and organs is usually precluded by fibrotic reactions that lead to scarring.Scarless Wound Healing And... · Regeneration In Anurans · Amphibian Immunology
  109. [109]
    Comparative regenerative mechanisms across different mammalian ...
    Feb 23, 2018 · Regeneration is dependent on an initial inflammatory phase for tissue debridement and protection from invading microbes. However, the immune ...
  110. [110]
    Next-Generation Sequencing in the Field of Primary ... - NIH
    Mar 5, 2021 · Currently, over 400 different disorders have been described, arising from defects in 430 genes. Of all known PID genes, NGS already accounts for ...
  111. [111]
    Population Prevalence of Diagnosed Primary Immunodeficiency ...
    Nov 1, 2008 · The calculated prevalence of diagnosed immunodeficiency was 1 in 2000 children, 1 in 1200 people of all ages, and 1 in 600 households. The 95% ...
  112. [112]
    Inherited immunodeficiency diseases - Immunobiology - NCBI - NIH
    The commonest forms of autosomally inherited SCID are due to adenosine deaminase (ADA) deficiency ( Image clinical_small.jpg Adenosine Deaminase Deficiency ...
  113. [113]
    Immunodeficiency - StatPearls - NCBI Bookshelf - NIH
    Primary immunodeficiency leading to B-cell deficiency includes X-linked agammaglobulinemia, also called Bruton agammaglobulinemia.
  114. [114]
    HIV and Malnutrition: Effects on Immune System - PMC - NIH
    HIV causes immune impairment leading to malnutrition which leads to further immune deficiency, and contributes to rapid progression of HIV infection to AIDS.Missing: chemotherapy | Show results with:chemotherapy
  115. [115]
    Secondary Immunodeficiency in Hematological Malignancies
    Oct 25, 2021 · Secondary immunodeficiency is reported in most patients with hematological malignancies such as chronic lymphocytic leukemia and multiple myeloma.Missing: malnutrition | Show results with:malnutrition
  116. [116]
    About Primary Immunodeficiency (PI) - CDC
    May 15, 2024 · Infections that most people don't get (sometimes called opportunistic infections). Lack of weight gain or growth in an infant (failure to thrive).
  117. [117]
    Primary immunodeficiency - Symptoms & causes - Mayo Clinic
    Primary immunodeficiency ; Symptoms · Getting infections often, including pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections.
  118. [118]
    [PDF] Strimvelis for the treatment of adenosine deaminase ... - NICE
    Sep 28, 2017 · immunoglobulin replacement therapy o Stay in ... SCID survivors treated with HSCT in. Newcastle included 12 patients with ADA-SCID.
  119. [119]
    Gene therapy for severe combined immunodeficiencies and beyond
    Dec 11, 2019 · ADA deficiency can be successfully treated with allogeneic HSCT, although the results to date are not as satisfactory as they have been for ...
  120. [120]
    Gene therapy | Immune Deficiency Foundation
    In 2016, the European Medicines Agency (EMA) approved an ADA-SCID gene therapy product called Strimvelis that uses a gammaretroviral vector. Thirty-three ...
  121. [121]
    Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine ...
    May 11, 2021 · Treatment of ADA-SCID with ex vivo lentiviral HSPC gene therapy resulted in high overall and event-free survival with sustained ADA expression, ...
  122. [122]
    Type III Hypersensitivity Reaction - StatPearls - NCBI Bookshelf
    Sep 15, 2025 · For patients with chronic immune complex diseases such as SLE, rheumatoid arthritis, or IgA nephropathy, education should stress medication ...
  123. [123]
    Type I Hypersensitivity Reaction - StatPearls - NCBI Bookshelf - NIH
    Aug 3, 2025 · Type I or immediate hypersensitivity is an exaggerated immunoglobulin E (IgE)-mediated immune response to allergens such as pollen, dust mites, ...Continuing Education Activity · Introduction · Evaluation · Treatment / Management
  124. [124]
    Immediate Hypersensitivity Reactions - Medscape Reference
    Nov 12, 2024 · The traditional classification for hypersensitivity reactions is that of Gell and Coombs and is currently the most commonly known classification ...Background · Pathophysiology · Epidemiology
  125. [125]
    Type II Hypersensitivity Reaction - Abstract - Europe PMC
    Type II hypersensitivity reaction refers to an antibody-mediated immune reaction in which antibodies (IgG or IgM) are directed against cellular or extracellular ...
  126. [126]
    Type II Hypersensitivity - an overview | ScienceDirect Topics
    Hemolytic anemia is the lytic destruction of RBCs (hemolysis) caused by a pathological antibody in a type II HS reaction (refer to Fig. 18-5A). The destruction ...
  127. [127]
    Type III hypersensitivity: Video, Causes, & Meaning - Osmosis
    Type III hypersensitivity is a type of immune response in which antigen-antibody complexes accumulate in the tissues and cause inflammation and tissue damage.
  128. [128]
    Breaking Immunological Tolerance in Systemic Lupus ... - Frontiers
    SLE is a prototype type III hypersensitivity reaction in which immune complex depositions cause inflammation and tissue damage in multiple organs. Two ...
  129. [129]
    Type IV Hypersensitivity Reaction - StatPearls - NCBI Bookshelf - NIH
    May 4, 2025 · Type IV hypersensitivity reactions are T-cell–mediated immune responses that typically develop 48 to 72 hours or longer after exposure to an antigen.Introduction · Etiology · Pathophysiology · Evaluation
  130. [130]
    Diagnosis and Management of Contact Dermatitis - AAFP
    Aug 1, 2010 · Allergic contact dermatitis is caused by a type IV, T cell–mediated, delayed hypersensitivity reaction in which a foreign substance comes ...
  131. [131]
    Delayed Hypersensitivity Reactions - Medscape Reference
    Oct 14, 2024 · Undesirable consequences of delayed-type hypersensitivity (DTH) reactions include illness such as contact dermatitis and allograft rejection.
  132. [132]
    Th2 Cytokines and Atopic Dermatitis - PMC - PubMed Central - NIH
    In this review we present genetic and functional data that supports a role specifically for altered Th2 responses, in the development of AD. Here we discuss ...
  133. [133]
    Transcription factor defects in inborn errors of immunity with atopy
    Aug 31, 2023 · This review examines TF defects underlying IEIs with severe atopy as a defining clinical phenotype, including STAT3 loss-of-function, STAT6 gain-of-function, ...
  134. [134]
    Primary atopic disorders | Journal of Experimental Medicine
    A large number of SCID-associated genes, as well as atypical complete DiGeorge syndrome, have now been reported to present with this severely Th2-skewed ...Impaired Tcr Signaling And... · Altered Cytokine Signaling · Mast Cell Deregulation<|control11|><|separator|>
  135. [135]
    Mechanisms of Bronchial Hyperreactivity in Asthma and Chronic ...
    Jun 25, 2003 · Bronchial hyperresponsiveness (BHR) is defined as excessive bronchial narrowing and manifests itself as an exaggerated bronchoconstrictor ...
  136. [136]
    Airway hyperresponsiveness in asthma: The role of the epithelium
    Feb 21, 2024 · Airway hyperresponsiveness (AHR) is a key clinical feature of asthma. The presence of AHR in people with asthma provides the substrate for bronchoconstriction.
  137. [137]
    Food Allergies: Causes, Common Examples & Cures
    The most common food allergies are peanuts, tree nuts, fish, shellfish, egg Nine foods account for most food allergies. But you can be allergic to any food.Food Protein-Induced... · Get Food Allergy Treatment · Milk Allergy · Wheat Allergy
  138. [138]
    Global, regional, and national epidemiology of allergic diseases in ...
    Jan 31, 2025 · The prevalence of allergic diseases has experienced a significant rise over the years, currently impacting approximately 10 to 30 percent of ...
  139. [139]
    Chronic inflammation in the etiology of disease across the life span
    Dec 5, 2019 · Inflammation is an evolutionarily conserved process characterized by the activation of immune and non-immune cells that protect the host from ...
  140. [140]
    Inflammatory responses and inflammation-associated diseases in ...
    Stimuli activate inflammatory cells, such as macrophages and adipocytes, and induce production of inflammatory cytokines, such as IL-1β, IL-6, TNF-α, and ...
  141. [141]
    Immunity and Inflammation in Atherosclerosis | Circulation Research
    Jan 17, 2019 · Atherosclerosis is a chronic inflammatory disease of the vessel wall that is largely driven by an innate immune response through myeloid cells ...
  142. [142]
    NLRP3 Inflammasome and Inflammatory Bowel Disease - PMC
    Feb 28, 2019 · Here, we comprehensively review the current literature regarding the physiology of NLRP3 inflammasome and its potential roles in the pathogenesis of IBD.
  143. [143]
    Inflammation and atherosclerosis: signaling pathways and ... - Nature
    Apr 22, 2022 · Atherosclerosis is a chronic inflammatory vascular disease driven by traditional and nontraditional risk factors.
  144. [144]
    Effects of cytokine signaling inhibition on inflammation-driven tissue ...
    Apr 10, 2021 · These efforts have mainly focused on four cytokine families: IL-1, TNF-α, IL-6 and TGF-β. This review will describe the roles of these cytokines ...
  145. [145]
    Understanding fibrosis: Mechanisms, clinical implications, current ...
    These mechanisms include an exaggerated inflammatory response, excessive activation of fibroblasts, and abnormal tissue remodeling following severe or ...
  146. [146]
    Immune mechanisms of granuloma formation in sarcoidosis ... - JCI
    Jan 2, 2024 · In this Review, we perform a mechanistic interrogation of the immune activities that contribute to granuloma formation in sarcoidosis and compare these ...
  147. [147]
    Adult-Onset Still's Disease: Clinical Aspects and Therapeutic ...
    Adult-onset Still's disease (AoSD) is a rare systemic autoinflammatory disease characterized by arthritis, spiking fever, skin rash and elevated ferritin levels ...
  148. [148]
    The Role of Adipokines in Inflammatory Mechanisms of Obesity - PMC
    Adipokines are currently widely studied cellular signaling proteins produced by adipose tissue and involved in various processes, including inflammation.
  149. [149]
    Calcineurin Inhibitors - StatPearls - NCBI Bookshelf - NIH
    Nov 12, 2023 · Mechanism of Action​​ By selectively inhibiting calcineurin, these drugs disrupt the transcription of IL-2 and other cytokines within T ...
  150. [150]
    Review of two immunosuppressants: tacrolimus and cyclosporine
    Both tacrolimus and cyclosporine function as immunosuppressants by inhibiting calcineurin, which downregulates IL-2 and other cytokine gene translations, and ...
  151. [151]
    Immunosuppressive therapy with rituximab in common variable ...
    May 6, 2019 · RTX depletes B cells primarily through three different mechanisms: antibody-dependent cell-mediated cytotoxicity (ADCC), complement-mediated ...
  152. [152]
    Tumor Necrosis Factor Inhibitors - StatPearls - NCBI Bookshelf
    Jul 3, 2023 · Mechanism of Action​​ This signaling leads to activation of the target cell leading to the inflammatory and immune response by releasing several ...
  153. [153]
    A Review of Immunosuppression and Pulmonary Infections - PMC
    Immunosuppression has improved graft survival but leaves the patient susceptible to infectious complications, of which pulmonary infections are the leading ...Immunosuppressants · Antimetabolites... · Specific Infections
  154. [154]
    Advances in the development of personalized neoantigen-based ...
    In this Review, we discuss advances in the development of personalized neoantigen-based vaccines, current understanding of the T cell phenotypes ...
  155. [155]
    Neoantigens: promising targets for cancer therapy - Nature
    Jan 6, 2023 · Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, ...
  156. [156]
    Cancer/testis antigens, gametogenesis and cancer - Nature
    Jul 20, 2005 · Cancer/testis (CT) antigens are normally expressed by gametes and trophoblasts, and are aberrantly expressed in a range of human cancers.
  157. [157]
    Mechanisms controlling PD-L1 expression in cancer - PMC - NIH
    Immune checkpoint programmed death-ligand 1 (PD-L1) plays a critical role in facilitating tumor immune evasion. Cha et al. discuss the mechanisms regulating PD- ...
  158. [158]
    Cancer Immune Evasion Through Loss of MHC Class I Antigen ...
    Mar 9, 2021 · Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021 Mar 9:12:636568. doi: 10.3389/fimmu.2021.636568 ...
  159. [159]
    [PDF] 1 This label may not be the latest approved by FDA. For current ...
    Initial U.S. Approval: 2011. WARNING: IMMUNE-MEDIATED ... Genetically engineered mice heterozygous for CTLA-4 (CTLA-4+/-), the target for ipilimumab,.
  160. [160]
    Resistance mechanisms in melanoma to immuneoncologic therapy ...
    These treatments resulted in an overall response rate of 10%-20% with little effect on survival and durable long-term benefit in less than 10% of patients.
  161. [161]
    FDA approves axicabtagene ciloleucel for large B-cell lymphoma
    Oct 25, 2017 · On October 18, 2017, the Food and Drug Administration granted regular approval to axicabtagene ciloleucel (YESCARTA, Kite Pharma, Inc.)
  162. [162]
    [PDF] BLA Clinical Review Memorandum, October 5, 2017 - YESCARTA
    Oct 5, 2017 · The clinical review team recommends regular approval of axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory ...
  163. [163]
    FDA grants regular approval to blinatumomab and expands ...
    Jul 12, 2017 · On July 11, 2017, the U.S. Food and Drug Administration approved blinatumomab (BLINCYTO, Amgen Inc.)
  164. [164]
    Drug Approval Package - accessdata.fda.gov
    Jan 12, 2015 · Blincyto (blinatumomab) Injection Company: Amgen, Inc. Application No.: 125557. Approval Date: 12/03/2014 · Approval Letter(s) (PDF) · Printed ...
  165. [165]
    Evolution of Adaptive Immune Recognition in Jawless Vertebrates
    Jawless vertebrates use variable lymphocyte receptors (VLRs) for immune recognition, unlike jawed vertebrates' VDJ recombination, and this is an independently ...
  166. [166]
    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-blinatumomab-and-expands-indication-include-philadelphia-chromosome
  167. [167]
    The Structure and Development of the Thymus in Fish, with special ...
    It has long been undisputed that the thymus originates in all vertebrates from the wall of one or more gill-clefts ; buds arise from the pharyngeal epithelium ...Missing: evolution | Show results with:evolution
  168. [168]
    Emergence and Evolution of Secondary Lymphoid Organs - PMC
    The spleen, especially the spleen's lymphoid compartment, the white pulp (WP), has undergone numerous modifications over evolutionary time.
  169. [169]
    Anopheles gambiae phagocytic hemocytes promote Plasmodium ...
    Feb 8, 2025 · Hemocytes (macrophage-like cells in invertebrates) are specialized immune cells that carry out a variety of immune defense processes such as ...
  170. [170]
    Dopamine modulates hemocyte phagocytosis via a D1-like receptor ...
    Jul 16, 2015 · Phagocytosis is an important innate immune response against pathogens and parasites. In the lepidopteran insects, the 'professional' phagocytes ...
  171. [171]
    Phenoloxidase: a key component of the insect immune system
    Nov 10, 2011 · The main role of PO in melanogenesis is to convert phenols to quinones, which subsequently polymerize to form melanin (Figure 1; Söderhäll & ...
  172. [172]
    Autophagy and innate immunity: Insights from invertebrate model ...
    In this review, we summarize studies from the fruit fly Drosophila melanogaster and the nematode Caenorhabditis elegans that highlight the roles of autophagy ...
  173. [173]
    PEBP balances apoptosis and autophagy in whitefly upon arbovirus ...
    Feb 11, 2022 · Our results demonstrate that a mild intracellular immune response including balanced apoptosis and autophagy might facilitate arbovirus preservation.
  174. [174]
    Trophallaxis and prophylaxis: social immunity in the carpenter ant ...
    Jun 30, 2010 · In social insects, group behaviour can increase disease resistance among nest-mates and generate social prophylaxis. Stomodeal trophallaxis ...
  175. [175]
    Social Immunity: Emergence and Evolution of Colony-Level Disease ...
    Jan 7, 2018 · This colony-level protection is termed social immunity, and it enhances the health and survival of the colony.
  176. [176]
    Epigenetic remodeling in insect immune memory - PMC
    The distinctive and targeted nature of immune priming has led to the investigation of specific genes as a potential catalyst for bolstering immunity. The ...Dna Methylation And Histone... · Immune Priming Within A... · Figure 1
  177. [177]
    Immune priming in the insect gut: a dynamic response revealed by ...
    Jul 28, 2025 · Immune priming is the ability of evolutionary ancient innate immune systems to provide protection against previously encountered pathogens. To ...
  178. [178]
    Variolation - Smallpox - National Library of Medicine - NIH
    In 1717, Lady Mary Wortley Montagu, the wife of the British ambassador, learned about variolation in Constantinople. In 1721, at the urging of Montagu and the ...
  179. [179]
    Edward Jenner and the history of smallpox and vaccination - NIH
    Lady Montague was so determined to prevent the ravages of smallpox that she ordered the embassy surgeon, Charles Maitland, to inoculate her 5-year-old son. The ...Missing: Montagu | Show results with:Montagu
  180. [180]
    The History of Variolation - HistoryOfVaccines.org
    Jun 5, 2021 · In China, scabs from smallpox pustules would be dried in the sun and then inhaled by people seeking to be inoculated. The drying of the scabs ...Missing: 10th century 1718
  181. [181]
    Emil von Behring: The founder of serum therapy - NobelPrize.org
    Dec 3, 2001 · In 1890, together with his university friend Erich Wernicke, he had managed to develop the first effective therapeutic serum against diphtheria.
  182. [182]
    History of smallpox vaccination - World Health Organization (WHO)
    It wasn't until May 1796 that the world's first vaccine was demonstrated, using the same principle as variolation but with a less dangerous viral source, cowpox ...
  183. [183]
    Ilya Mechnikov – Biographical - NobelPrize.org
    Nobel Prize in Physiology or Medicine 1908 · Summary; Laureates ... discovered the phenomenon of phagocytosis with which his name will always be associated.
  184. [184]
    Phagocytosis: The Legacy of Metchnikoff - ScienceDirect.com
    Aug 25, 2016 · Nobel awards to Metchnikoff and Ehrlich in 1908 and to Steinman, Beutler, and Hoffmann in 2011 bookend these two phases of discovery, linked ...
  185. [185]
    Emil von Behring – Facts - NobelPrize.org
    In 1900 Behring introduced serum from immune horses as a method to cure and prevent diphtheria.
  186. [186]
    Emil von Behring and serum therapy - ScienceDirect.com
    He injected untreated guinea-pigs with diphtheria toxin and treated them afterwards with sera of animals that had survived the disease. The success enforced his ...
  187. [187]
    Paul Ehrlich (1854-1915) and His Contributions to the Foundation ...
    Feb 5, 2016 · In 1897, Ehrlich formulated his 'side-chain theory', which soon became the basis of immunologic research (table 3).Missing: authoritative source
  188. [188]
    Peter Medawar – Nobel Lecture - NobelPrize.org
    Nobel Lecture, December 12, 1960. Immunological Tolerance. “Immunological tolerance” may be described as a state of indifference or non-reactivity towards a ...
  189. [189]
    Approaching the asymptote? Evolution and revolution in immunology
    Approaching the asymptote? Evolution and revolution in immunology. ... 1989:54 Pt 1:1-13. doi: 10.1101/sqb.1989.054.01.003. Author. C A Janeway Jr ...Missing: text | Show results with:text
  190. [190]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6738855/